!

-

19/03/2023

, .

:


- . 
. , , .


- . 
, , . .


– . 
, , .


– .
.

, , .


, (, , -), .

 |   |   | - |  | 

 

 

  1. :     .
  2.  

 


.  .
.  .
.  .
.  ( ) .
.  ( ). 
.  – .

 

, .

 

-

 |   | 

 

, , .
, .

 

-DNA . , ( , , , , ). , , , 1-3.
. : CRP, serum amyloid A, TNF receptor2, -8 4-5.
-1β, -6 -10 6.
-1β β   7.

-8, CRP -serum amyloid A   8.

II-IV. CRP 9.

.
( ), 10; 6 11; 12.
, (DII) . , 13. -, 14.

 

?
, .

15 2016 ( A2 (cPLA2), COX, LOX , ). , . .
( ), ( ), (), (DAS) (), ( , ), EGCG ( ), ' (, , , , ), (, , , ), (), 6-'' (''), -3- ( ), (), C- ( ), ( ), ( ), ( , ), ( ), (), ( ).

(, + ) 16.
, ( ). CRP, TNF-α -6, 17-18
CRP, TNF-α - 6 19.
, , , CRP 20.

 


, , . 
, :

  1. , , . -10 . .
  2. . , , .
  3. , . .
  4. , : , , , , '' '.
  5. 3, , , ', .
  6. .
  7. : , , , , '. , , '.
  8. : , , '. .
  9. .
  10. . , ( ), .

: .

 

 


. () , . insulin-like growth factor) IGF)  . -IGF , . 
, , . , 21.

, , ATP ( ) . 
: , , , , , 22.
2-3. , -67% 23.
, 24.
, (, '). (Stevia rebaudiana) 25.

 

-

 

( , '), , , , , . , .
, ( ) ( , , ). ( , ). , ( , , ) ( , , ).

 

 


, , (: -, ). , , 26
, , 27
, (, , ) 28.

, , , . : , , , '', , , ( : , , ). , . , . 
, , , .
. , '.

 

 


.
, , () , ' , . , , .
:
/ . 
(doxorubicin, adriamycin) , , 29.

(20-500 " " ) , 30-33. , . 
, (Fluoroplex, Doxorubicin, Bleomycin) , .
, 34-37
, ( ). , .

- 38, , 39-40.
() . , , , 41-43

. - 44tamoxifen, trastuzumab, paclitaxel, (45)cisplatin  46 (5-Fluorouracil). , Cyclophosphamide 47. .

, , Etoposide, Temozolomide) 48), Cisplatin) 4950 (Fluorouracil-5, 5-FU plus oxaliplatin/FOLFOX).

, . , .

, (51)
(52)

 



.
  .

 

:

 

:

 |   |  |  ,  |  A

 

 

 

, . , . 
, . , . 
, , .
. , , . ( A, BPA). , BPA, 53
, , .

 

 

3 , , . , DHA (, , ) 54-55. 3 : 56-57, 58 59, 60

, - (, , , ), 3. ( ) . 
3 , ( ). 

 

3:

3 ( -). (0.7%-1.5% ). : , . 61-62. 63. , , , , . 64.

' (Salvia hispanica) ' -2.5 , 5 , 2 , (9% ), (15%), , ; ( , ) 65-67.
, ' 68 69.

 

 

()

, , , . .
, , , , 70-74. , 75.
, / , -'76. , VEGF -VGEF-2 77.

 

 

 

: ( , /, , ', , , ), , , , , , .
64.
(NK cells) 78. -3- (I3Cs), , , 79-81.
: 82,83, 84,85.

* . .

 

 

: , , , , .
-2 64.
: , , , . (: ) -, . , ( COX -LOX) ()86.
, . , .
, , , , , 71.
, 87.
* ().

 

 

, , , 88,89. 71.
2-3 -40%-50%. , , 89
, , 90,91. (, ) .
( ) 68.
, , , A.
( , , ). (-, -, - ). ( ) 92.
- 93. , - 94. , - VEGF ( ) 95,96.

 

 

 

. : , ( ), , , , , .
, , , ,  97,98NF-kappaB.
, , 99-103.

 

 

( ) HER2 . , , , , ,  104. 105, VEGF ( ), COX2 -MMPs 106-108.
, 109-111.
.
, , ( , ). 

 

 

 

( , ), ('), , , , , , , , , NF-kappaB, COX2, TNF, PGE2 112-114
, , , . 
, (tamoxifen, trastuzumab, 44(paclitaxel,  45cisplatin  46 (5-Fluorouracil). , Cyclophosphamide 47.
(Radioiodine) , -115DNA.
. ROS. " , , , . 116-118.
, 119.

 

 

: , , , , K, A, .
(Undaria pinnatifida), (Laminaria japonica) (Hizikia fusiforme). . 
, () 120. -1 -TNF-α 121ROS.
(Fucoidan), : NF-kappaB, VEGF ( ) 122,123.  , , 124-126.
(Fucoxanthin) , , , 127-129
, 130,131. 2012 ( ) , 132.
, 2016 , , 133.
" 0.15 " .
29.3-45.8 "/"; 93.9-185.1 "/"; 241-4921 "/"134.
. , , (). , . 135.
136NF-kappaB.

 

 

 
, ( ). ( ), , , D2 ( ). , , 137,138.
*:
Ganoderma lucidum (), Lentinula edodes (), Grifola frondosa (), Trametes Versicolor (, ), Cordyceps sinensis (), Flammulina Populicola (), Agaricus Blazei ().
* , .
, 139. 140 (VEGF).
, K, , , ( )141. - (, , , ) ( -β1, IL-6, TNF-α, E2, )142.
( ) PSA . : IL-2, IL-4, IL-6, IL10, IL12, TNF-α ,  CD4+, CD8+ -NK ( )143. 144.
CYP2D6 Doxorubucin. Methotrexate, 6-mercaptopurine, tegafur/uracil, Cisplatin, Cytarabine -dexamethasone 143.

 

 

 
: , , , , , , , , . 
( ), :
ROS, NF-kappaB -8 145.
, , 71,146,147.
58. 148. 8 , -, -, + 149.
, - (, , , ), -' (30% -50% ). 150.

 

 

( ) 
: , , , , '.
C , NF-kappaB, TNF, Cox2 . , , 112
. 151. 152,153.
, (', ', ), 154. , 155
156.
, , , 157-161.

 

 

" " ("Drupe, "Stone fruit)
. : , , , , . , , .
(, ), , 162-164.
. 2-3 ( 60 ") 165.
, , 162. .
( ) E. 166.

 

 

 
: , , , , , .
64.
( , ) 167  , -168DNA.  169
, . 162.
170.
, , 112,  162UVB.
( , ). 
( ), ( ) , .
   .

 

 

 
' NF-kappaB, COX2 112. . , , , 162,171-173
, , , PSA , , 174.

 

 

 
NF-kappaB, COX2 112,175. , 176.
10 "/" 177.
 (5-Fluorouracil- 5 (FU 178.
, . , . : , - ( , ), , ( , )179-182.
   .

 

 

 
: , , , , , , , ( , ).
, 183. 46% () 76% ( ), . 3 6, 3:6 (1:4)184. , 3, . 2.5 ' .
( B, E) (, , , ). . : ( ), ( , ), () . , ( , )185.
-EPIC ( ) 16 ' 186.  28 ' 187.

 

 


3 ( -). (0.7%-1.5% ). : , . 61,62.

63. , , , , . 64.
' (Salvia hispanica) ' -2.5 , 5 , 2 , (9% ), (15%), , , ( , )65-67.
, ' 68  69.
, COX2, NF-kappaB 15.
188.
, , . . 80 "/" 189.

 

 

 

: , , , , , , , .
, , , ( ) . , , , , 190-193.
(, , ) 194.
" ", , , -195COPD.
* 193.

 

 

 
- (, ). , 196.  , 197  198. , NF-kappaB 112.
(Lunasin) , ,  199(NK), , , , 200-202. , .
(, , , ') , 203

, , 64.

 

 

''
, , :  '' ''
, '' NF-kappaB TNF-α 204.  - 205TNF-related apoptosis-inducing ligand) TRAIL). '' 206. -6 (doxorubicin, paclitaxel, 5-fluorouracil, platinum) , ( ). 207.

, '' , . 0.5-1 ' ( ), -3 6 208-210

 

 

 
,  EGCG) epigallocatechin gallete), , , . , NF-kappaB, COX2 -211,212
EGCG , 212. (', ' ') -213EGCG.
, / , 214-217. , , , 218,219.
Docetaxel 220.

2-3 , 2 ' ( 5 ). 

 

 

 
NF-kappa B, TNF-α222 -IL-6, IL-8, IL-12) 112,223).

100 ' 1.6-4.8 ' 221 12 ' -3 . 

: , , , , , , , , , 221,224-228
, , -223,224,229-231DNA. 
, Etoposide, Temozolomide)48), Cisplatin)49) 50 (Fluorouracil-5, 5-FU plus oxaliplatin/FOLFOX).
:
, . , . , 51.
, NF-kappaB 232.
, . : β-sesquiphellandrene -233-235Turmerone.
.
, 236-238  239-240 ( – Piper nigrum) .

 

 

 (70% ) 
, . , 241.
(20 ', 2-3 ) CRP 242
, 243,244.

 

 

 |   |  |  ,  |  A 

 


. , . (IGF (insulin-like growth factor . -IGF , . 
, , . , 21.
: , , , , , 22.
2-3. , -67% 23.
, 24.
, (, ').
(Stevia rebaudiana) 25.

 

 


245,246, , .
-EPIC 2008, 35 -32 247.
, , ( ), , 51% -56% 248
-' (NHL), – ( ) -NHL -5% 200 '/ -6 249.
. 60%-80% , 246 : , , DHEA, , 250
, . 251-253
 ( ) 254 .
, -2000 " 255
IGF-1. , (BCAA) , mTORC1 256.
, , 257
. , , 258.
259,260 261-263

 

 


-20-30% 264,265, , , , , , , , 257,266-270.
270,271,266,264: heme . , , , (heterocyclic amines) - - (polycyclic aromatic hydrocarbons). ( ) (, , ).
, , 6 .
-500 , , 266.
. . , . , IGF-1 . , , (ATP), 272.
, .
( 3 ), -15%-20%. (4 ) . 270.
. , , . . , , , , .

.

 

 

, ,  
, 273-275.
, .
- ( ).   , , 276. BPA) A) -diethylstilbestrol .
- ( , )277. , .
, , , 278.
( ), .
. , (E-250) 279. (E-211) 285. (E-212) , 281. 282
, 4-methylimidazole 283

 

BPA) A, )

, -PVC ( ). PVC : , . PVC , / , BPA , , 276.
BPA, (Phthalates) , TNF-α, CRP 284.
BPA , 285
-BPA BPA 286,287.
, BPA ( )288.
. , .

 

 


 


 |   |   |  ? |  |   | 

 

289, 2014 " (PCRM), .
, , .
:

  1. .
  2. , , , .
  3. .
  4. , , , , .
  5. .
  6. .

 

 

- . 3 6, () . 
, , 56% -3 : , . , , 290.
( )

 

 

 

, , . 
ATP , 272. , , . 
. . -13 -36% 13 . , ( ) -13 .
, -HbA1C 291
, .
, .

 

 

?


. ( ) , .
( , ,
292,293.
. , . , . 294, .
, , 295, . 
, ; .
, . , -'296.
, ( ), "" .
( 2016): , , , , , , , , , , , , , , , , , , .

* : http://www.ewg.org/foodnews

 

 

 

, , 251,297.
, , , . . TNF-α 298, -1β. , , , , , 299.
, . -14% -20% 300. 2003 . , .

 

 


( ), , , , .
3:6, , 301.
. , .
-EPIC, -200,000 , (12%) (10 ) 302,303. 304.
: ( 17%), (27%-33%), (10%), (4%), (42%); 305. , , .
306
, 307 308-310 .
.

 

 


, . . ( )311 . , 312.
. , ( ) .
-3 " 33 , ( 20-50 ' ) 313-315 . , ( ). 131 ! 
, , . , .
316. , . 10 , 317
, , , . (50-70 "/") . 2 ' (" 30 ) . -6 . -30 318.
20 , 319.
, . .
, , 80 -116 114. , ( ) 316.
(, ), : , , , , , . , ( ), , 320.
, . .
, , .

 

 

 


.
.  , .  . , , .
.

?   .

 
  1. , (, , '), , .

 

  1. . , ,

 

 

  1. , . .

 

 

  1. , : , , , , '' '.

 

 

  1. 3, , , ', .

 

 

  1. .

 

 

  1. : , , ,  , '.  , , '.

 

 

  1. : , , '. .

 

 

  1. .

 


  1. . , ( ) .

 

 

 

     ?   .

 
 

 


, , , .
, , , .
, . , , . , .

, , , . , . , . 

:
' (Panax ginseng) - , ' (Panax ginseng) , . ' () . , ' , , , . ' .

(Ganoderma lucidum) , (, , , , ) . , , . , . . , , , . 
.

(Astragalus membranaceus) - (20-60 " ) . , . , , , ( , , , , , , ), . .

' (Panax quinquefolius) - ' . ', -DNA . ( ) ' 8 . , ' (' ) . , ' , . ' , . / , , , , , , . ' .

(Silybum marianum) - , : , , . 
, . .

(Curcuma longa) - , . , ( ) . , ( ) : , , , , , , / , , .

(Glycyrrhiza glabra) - . . , , , , , , . , ( ), .   
. . 

 

 

 

. .
– , ,

Curcuma longa, Scutellaria baicalensis, Boswellia spp, Glycyrrhiza glabra '227,321-324.

( ).
Gymnema sylvestre, Momordica charantia, Cinnamomum zeylanicum '325.

, , ( ).

 

 

 

, ( , '), , , . , .

, . 
, . , ( )326-328. , .
, , , 329-334.
Astragalus membranaceus , , 335,336.

Panax ginseng , 337. ' 338.

Withania somnifera   , 339.

Ganoderma lucidum . 340.

 


, :

Panax ginseng, Panax quinquefolius, Eleutherococcus senticosus, Rhodiola rosea

, ,

Withania somnifera, Centella asiatica, Ocimum sanctum

, , .

 

: 
Astragalus membranaceus – (), , , , , .
Glycyrrhiza glabra – ( – ), : , (, ) .  , :  .
Ganoderma lucidum – , , , , , , .
Schisandra chinensis –  ( , ),  , .
Cordyceps sinensis – , , , .

Lepidium meyenii –  ( , ) , .
Panax ginseng – , , , , , , , .

Panax quinquefolius - , ,
Eleutherococcus senticosus – , , , , , .
Grifola frondosa – , , , .
Withania somnifera – , , , , ( ).
Centella asiatica- : , , , , , , .
Ocimum sanctum – , , , (, , , ), , ,
Rhodiola rosea – , , , ,
Codonopsis pilosula – , .

 

, .  :

. ( , , ,MBSR ), , / , : Withania somnifera, Centella asiatica, Verbena officinalis, Rhodiola rosea, Melissa officinalis, Scutellaria lateriflora 341,342
, . 
343-345 (folia Urtica dioica, Zea mays, Folia Taraxacum officinalis), Verbena officinalis, Matricaria recutita346), Viburnum spp., Valeriana officinalis347,348) 349-350 (Crataegus spp., Salvia miltiorrhiza). 
//, : Withania somnifera, Astragalus membranaceus, Cordyceps sinensis 333,339,351.
( , ) (Withania somnifera, Panax ginseng) (Valeriana officinalis, Passiflora incarnata) 339,352,353,354.
, , , . :
Gymnema sylvestre, Panax quinquefolius, Momordica charantia, Ganoderma lucidum, Silybum marianum 325,330,355,356.

 

 

–  

 

. , .
, .
  : Curcuma longa, Ganoderma lucidum, Scutellaria barbata 332,357,358.

. , .
, .
:

Curcuma longa, Momordica charantia, Panax ginseng, Ganoderma lucidum, Scutellaria barbata 722-725,332,357,358

, " (Momordica charantia) :

  1. , . 
  2. ( NK), , / .

, . .
 

 .   . 

( 100 ) . .

, , , (). :359-365,329

 
 

 

. ( ) . 
. , , , . " ".
. , .
. . , . 
, (-) .

 

:
 – , . :366-368 Silybum marianum, Schisandra chinensis, Ganoderma lucidum.
( cisplatin) , . , :369,349 

Crataegus spp., Astragalus membranaceus, Salvia miltiorrhiza.

.


 – , . , .
: / .
: Astragalus membranaceus, Ganoderma lucidum, Echinacea spp. '340,370,371.
: Withania somnifera, Angelica sinensis '372,373.

:
374-376 Glycyrrhiza glabra, Althea officinalis, Plantago spp.
/ Zingiber officinalis, Matricaria recutita, Chamaemelum nobile 377.
Taraxacum officinalis Radix Cynara scolymus,378,379.
380-382Taraxacum officinalis Radix, Arctium lappa, Althea officinalis, Glycyrrhiza glabra, Leptandra virginica , Ulmus rubra.
Astragalus membranaceus, Schisandra chinensis, Ulmus rubra 383-385.
386-388 Codonopsis pilosula, Glycyrrhiza glabra, Taraxacum officinalis Radix, Withania somnifera, Panax ginseng, Eleutherococcus senticosus.

 

 – , . .
, , : Ganoderma lucidum, Momordica charantia 389-390
, . , (Curcuma longa) Doxorubicin 391-393 Etoposide.
  .  .

 

 

 

:

  • .
  • , .

 

:

3 | 

  1.  

B |  C |  D |  E | 

 |   |  |  | EGCG |  (MCP)

 |   |  |  Q10

 


, .
, . .

 


3 | 

 

– .

, , ,  zyflamend 10 . 3 .

 

3
3 , , . , DHA (, , ), 54,55.
3 (, , , ), , ', ( ) .   .
, ,   .
3: , . ( ). 
3 (CRP, IL-1, IL-6, PGE2) ( , , , )394-398 ( )399. IL-10 ( ), , . 394 397,398   6:3 , IGF-1 . 

3 3 , 396.
3-5 ' 3 1-6 .
.

 

 


. . .
400,401  600-1000 " HbA1C . 402.

, 403
, 404,405.

 

 

–  

B |  C |  D |  E | 


, ( , '), , , , , . 
( ) 406,407, 408, SAMe 409. .
, . ( ). 
410 2016 (  C, E, ) . , ( ), /, / . , , . (Cachexia) .

(5 80 /) .
.

 

B |  C |  D |  E | 

 

B ( B)
B ( 2-3 ), B : 
, B .
, B B. .
, B . B, .
() . , /  411B. 
, B () .
B ( B12) -DNA . 412-414.
B  ( B2, B3 B5) . , .
B6 () , , (GABA - gamma aminobutyric acid), , , , , 415,416
B, B6, B12, , , , 417-420.
-2016, 18 B . ( ), B , 421
, B6 422. , 5 , B6 PLP ( B6) -30%-50%. B6. 7-35 "/" 423. 

(one-carbon metabolism) DNA, , , (NO) 424
, B6 , , 425,426.
: , , , , 427
, ( ) ( -16 -24.4 /") , BRCA 1/2 428-430ERβ. , .
– B , B . 
B12 (Cisplatin, Pemetrexed) 431. , , B2 432,433Cisplatin. 
, B6 (Cisplatin, Hexamethylmelamine) 434. 300 " , . B6
B3 TRAIL Tumor necrosis factor related apoptosis-inducing ligand  435.
, B . B, . 

 

 

C
C , , , , , , , , .
C , , -436-438DNA. , C 439,440, 441.
-US Department of Agricalture) USDA) -National Cancer Institute) NCI)  5 442. - , 200-280 " C 436.
C C . , . (50-200 ") 443
C ( ) ( 5 ) C . , 444-446
C ( 500 "/) , , . C 447.
C -448-451. C . 150 " -5% -21% 452.
, 500 "/ C 453,454.
- C , 455Gemcitabine. , C ( Ascorbate) (Carboplatin, paclitaxel) . , 456
C . -2014 C , C . C (, , , ) 457.

C , . C 458,459
C 1000 "/, ( Cisplatin) 460,461. , -2016 C -Cisplatin 462. , C Gemcitabine, Erlotinib, Paclitaxel, Carboplatin457. C 1 / 4 (Bortezomib, Melphalan) 463.
C. -2015 6 C ( , , ). 1 / 4 28 10 .

, 459. 5 / C () (cyclophosphamide, methotrexate, 5-fluorouracil) . 464
(500 " ) , B12, 465,466.
, C . . 

 

 

D
D . , D2 ( ), D3, ( , , , ) 467
D , , , 468
D (UVB). , , . , D . ( UVB) D . D. , 10,000-25,000 " D 15 . , , , 469

D 470.

/ D , : (60%-70% ), ' ( -20%-30%), , . D -23% 471-481
D , ,   482-487.

D ( 99 /) -37% 482. D ( -50 /) ( 72 /) 488.
D (400-1100 "/), (400-833 "/).

D 75 /489. D 1800-4000 "/490. (Institute Of Medicine) 4000 "/ 467.
D  . D , , , . , -2010 D ( 100) 491.
, D, . 

 

 

E
E , (, ), , (, , , , , ), , , .
E , -α, β, δ -γ. 
E (d-α-tocopherol). E (dl-α-tocopherol) E E 492-494. E ( ) E .
. - - - . E , -ROS . , , T B, 495COX.
E (-) 496. - , - 497.
, ( ) , (15 "), E ( 30 " -) (50 ") 42% , . 5.25 498.
400 " E 453,454.
E (Gemcitabine) 455.
-ATBC ( -1994) E -34% -41% , 499.

- ( ) 500.
E " " . -SELECT, -NIH , E (400 "/) . -17 501.
-ATBC , E (-) 50 " 499.
E E . , ( ) . 400 " ( -SELECT), E P450 . , 502.
, E Cisplatin. 400-600 "/ E (-) . 3 503,504

, E . . E (), E , , .

, E.

 

 


A () (, , , , , , ) (, , , , ). .
, , , 455,505-508
, 509.
(46%-), (57%-) 510,511.
, -CARET (  1996)  300 " 25,000 "  retinyl palmitate A , 28% 17% ( ) 512.

6 , , , ( ). , . 
-ATBC ( -1994) 20 " -16 499. 6 513.
-CARET, 6 -ATBC, -CARET ( ) 514.
, , . 

 

 

 

–  

 |   |  |  | EGCG |  (MCP)

 

, , .
, , , , .

 


. , , , DNA 515. ( , ) 516. , 517,518.
: ( ), , , , , ( ), , , , , , (, , ) . .
: , , 519-521.
( 55 -8 ) 522 ( , ), , .

, . , , . (The Nutritional Prevention of Cancer) 200 " ( 400 ") 523.
524-526. 527. 528.
IgG -IgA /. , 529
, DNA Cisplatin -Mitomycin. (Methyl selenol) 530(Sodium selenite). 
, (, , ) 531
100-400 ". -400 " (). 532.
, ( ), , .

 

, , - . : 35 " , 55 " -600 " . 6 .

PSA . 6 . -14 53 . 10 . 37 3 , .
- . 
. . , 533.

, ( ) 90,91, 400 "532.
. , , .
, , .

 

 

 
.
-DNA ( ), , ROS 534,535
, , , , , , , , , , ; , ( ) .
, -DNA, ( , , , - (SOD) ), ( , , , IGF-1), 536-539
, ( ) , , , . : , , , .
, . , . 540.
/ : , , , , / 541-546.

( -40%). ( )547,548.
( ) () , 549,550
551. , , 549.
( ), (-50%, ), , (. )542-554.
. 555. , NF-kappaB, -DNA, -p53 ( )556-558.

, ( 15 "/) 10 ( )559. , , , 560.
( ) 561Docetaxel.
-10 " , -50 " . (100 " ) .
, . , , . 
, (2016) .

 

 


. , 562-564.
: Heme -Nonheme . , , , , , . , , , , .
Heme , , : , , , , , , , 565-567
, , . , ( 120 ", E 30 ", 6 ",  100 " 20 ") 568.

( 18 ") 569,570. , 571.
, EPIC , Heme , 572,573(  Heme).
, , .

 

 


, , Polygonum multiflorum. , , ( NF-kappaB, TNFα (IL1, IL6, IL12)). , -DNA -RNA 407,574,575
. .

"-", . 576.

Bortezomib. -5 24 . 50% 577. 5 .
. 700 "/" , (2.5-5 ') ( , ).

1 578
. 579, ( 1 4 ) CYP3A4, CYP2D6) P450-CYP2C9)  CYP1A2. . , .

, , .
 

 

EGCG
-3- (EGCG) (Camellia sinensis), 407,580 , ( ), ( NF-kappaB COX2). , EGCG -DNA IGF1.
. , , .
- , , , , , , 580.
EGCG Cisplatin -Oxaliplatin 581. , EGCG 582. , EGCG 583.
EGCG ( ). EGCG .
( I II) EGCG . 440 / 584,585
EGCG VEGF HIF-1 α, 586  587.

(40-660 /) ( 24 , -EGCG 140 /).
 


(MCP)

(MCP) . pH , , . 
MCP 729; 730-731; ( NK ) 732; -3 ( ), 733. GCS-100 , 734
, 735; ( -3)736; , 737-738; , ( ) 737,739
MCP S-trans, transfarnesylthiosalicylic acid (FTS) ( ) 738.
-3 (galectin-3) : , , , , . , -3 T 740. -3 . , , -, , , , , . . , 741.
, -3 , 742. -3.
-MCP -3, -3 .
II 13 . 14.4 / MCP   . 7 10 (70%) , PSA 2.88. 3 13 ( ). 743
, .
 

 

 


 |   |  |  Q10 

 


. , , , . , " ".
, , . 
, . , (-) .

 

:
– , . / Q10.
– , . , , .
: , , : ( ) . 
. .
– , . .

 

, 588 , 589.
, (, , , , , , , ) , , , .
, ( ), 590,591.
, (, , , ) ( '). - 30 (), -5 , 14 589,592-594.
, 595,596
589,597,598.
, ( ) / .

, , ( ) -599-602.
, , , .

 

 

Reactive oxygen species ROS (, , ).
(DHLA) . , , ( E, C )603

ALA , , , , , , , , .
, , , 604,605
. ALA 606-608.
, ALA . ALA CD25 ( T ) -CD95 ( T ) 609,610.
ALA Cisplatin, Oxaliplatin -Docetaxel , , /. - 600 " , 1800 " (600 ", 3 ) 611,612.
Doxorubicin 613. ALA CK -LDH 614.
, -ALA , , 615-617 Doxorubicin.
600-1800 "/. . . , - . 
, , . , , .

 

 

, .
– , . : . , . , . , . , . , . , . .
, 618-620, 621  622.

-20% , B -C, 623-625. , , - , -626,627
. -. , (HPV) . HPV 628,629. () , (-20% 30 ).

( : . , . , . , . )630,631.
( 2 ), : , , , 632-638.

, : . , . . . , . . 2-3 4-12 / . 
, , . , ( 5.5 . , . , . -. ). , . 1-4 10 639-641.
, ( -) , , , 642,643. : 40 . + (GOS), 10 . (). 7-11 2-7 .
, , (. ) , 644.
645Cyclophosphamide.
(). -.

, , - . 646-649, , .
, 632,634. , , ( ) ( , )650.
, 651-656 (3 , ', ). 
, . . 
, ( ) . . .
( 10 ). , , . 
. , , .
. , .

 

 

Q10
Q10 . -DNA .
  Q10 , .
Q10 . 657.
-6 32 ( 90 " Q10 ). 300-390Q10 " 1-3 ! 658.
-Anthracyclines Doxorubicin -Daunorubicine , Q10 659. Q10 , ( ) . , 657,660-662.
Q10 . 300 "663. , Q10 100 " , 664 (CEA -CA15-3), 665.
, Q10 , .

 

 

 
-

, - .
, , , : " ?", " ?", " ?", " ?", " ?", " ?", " ?" .
- .

 

, , . . . - , , .
- , .
, :

  1. - . . : , ( ) (), , "", "" ( , , ...) . , . 
  2. Mindfulness Based Stress Reduction) MBSR) – "" "" ( ). , , , . 8 , 45 , 6 . . : , Hatha yoga . (!) , .
  3. - . , , , , , , ... . : , - ; / (: ). .
  4. - . , . . -5-7 . 15 , , - .
  5. - – , ' , ' . () , (Focusing) . ' ' - , (Life force) , .

.
, ( )666.
MBSR IL6, IL8 -TNFα, 667,668
669.
670  (PCOS). , 671. MBSR 672,673 674

 

, ( , '), , , .
, 675. MBSR . , 676,677
- . , ( Mindfulness), (, ' ' ). 48 78 678.
' 679,680, 681.

, () ,   .
--682. corticotrophin releasing Hormone CRH, (ACTH) , 683. .
, ( VEGF) 682,684.
, , , (NK cells), 685
MBSR, .
MBSR, 686-688.
, , 666.

 

–  

? , .
(, , ) , (NK cells) IL-1β -TNFα -48 689
, (, ) NK, CD25 ( T ), CD56 ( LAK) -CD3 ( T ). , 690,691.
( ) 11 . , (, , )692.

 

, - , .
, . , , , .
- , .
, , , .
MBSR , , , , 693-697. 696,697. MBSR , MBSR , , . , 698.
( ) , 699. 700. , 697,701.
, . , , , , , , , , 696.

 

-

, . 
, . , . 
. , . 
, . . , " ", – "" .
" ", ; , , , , – . , , . , .
? ?
. . 
- . " , . 
, - . , , .
; , , , ; . , - , , .
, , , . " . 
: , , , , "" .


 


, (, , -) .
, . .
, .
, .
" " , . . , , .
. .
. , , , .

 

 

 |   | 

 

  :

 

 |   |   |   |   | 

 

 |   |   |   | ' |   |   |  |   |  |   |   |   | 

 

 |  3 |  D |   | 

 


 |   |   |   |   | 

 

 

-  (2021) , (fast-mimicking diet – ), . 31 , -22 , . 

(12 ), ( ), ( ), ( ) ( ). 22 . , - . , . 

, , .  

https://pubmed.ncbi.nlm.nih.gov/33359756/

- , (2020) 6, , . 70 , -41 6, -24 6, . (23 17,546 ), (17 39,038 ), (14 10,541 ), (5 , 2,403 ), (3 1,756 ), (3 36,819 ) (6 2,958 ). 

:

  • 6 , -8% , . 

  • -, ( -13%), ( -9%), ( -12%). 

  • -, 5% 6 2% -3%, , . 

  • 6 . 

6 , . 6, 6 . , -0.2%.   

" .          

https://pubmed.ncbi.nlm.nih.gov/32825393/

-,(2019) 17 1,111 , .   

https://pubmed.ncbi.nlm.nih.gov/31855257/

-,(2019) 22 , , ( , , ) ( 2.45 "), ( 2.54 ") ( 150 ) .

https://www.ncbi.nlm.nih.gov/pubmed/30686742

- (2021) . - , ,

11 429 18. ( ) ( ), , . 

, , . , , .  

https://pubmed.ncbi.nlm.nih.gov/33964406/

- ( 2018) .

103 -40 , " 100 . , , , HDL , 2, . , , , . , . , .

, , .

https://www.ncbi.nlm.nih.gov/pubmed/29982151

 (2019) (REE - Resting energy expenditure), . 

https://www.ncbi.nlm.nih.gov/pubmed/31420208

 (2020) . , . , , . 

, (), (), -DNA, , , , . , - . - / . , . , , , , , . 

, .  

https://pubmed.ncbi.nlm.nih.gov/33271979/

 (2019) : 
•  , , ( - Solanum nigrum). - – , , , .
•  – (hematotoxicity), (hepatotoxicity) . 
•  , . 
, . 
http://www.sciencedirect.com/science/article/pii/S2225411018310083

 (2018) . ( ", ) , ". , , ( , , , ) .

, , , , , , , ', , . - , . , , . , .

https://www.ncbi.nlm.nih.gov/pubmed/28946660

 (2018) . , ,

:

  • 3 (EPA -DHA) - . 
  • Lactobacillus -Bifidobacterium .
  • , .

https://www.ncbi.nlm.nih.gov/pubmed/29943769

 (2020) - , - . , , - . 52 63 -BMI 25.4, , 12 . 

:

  • 3 . 

  • - (20 ) . 15 (5 ) -150 " . 

  • , , 1.2 /".   

, SPPB, , , , . 

SPPB, . , . 

, . 

https://pubmed.ncbi.nlm.nih.gov/32340904/

, (2020) , . , , . 26,218 35-69. , -13.5 , 15 . 

, (-85% -44% ), . , , . , .  

https://pubmed.ncbi.nlm.nih.gov/32751091/

( 2016) , , (HbA1c), (CRP), .

, , .
2,413 , , 27-70 . 24 , 4 .

-13 -36% 13 .

. , HbA1C .

, .

: .  

http://www.ncbi.nlm.nih.gov/pubmed/27032109

, (2018)  , . , 0-32, , 16 ( // ). , , , , , , , , , , , , , , , , . -70,000 44 . -7 1,340 ( 459 , 180 -135 ).

, , -25% , 5 8% . -, . -0.6% . , .

.

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2707948

( 2016) .

685 70 , 45% 55% .

12 87% . 89% , , 36% . 
, ( -) .

.

http://oncology.jamanetwork.com/article.aspx?articleid=2521357

( 2016) , , . 

12 , 10-61% . 

, 19-60% , 23-60% - 27-52% . .

http://www.ncbi.nlm.nih.gov/pubmed/27340121

(2021) (Salvia officinalis), . 88 64 , (). 

, . 78% -4 0-10. 

, . , . 

, .

https://pubmed.ncbi.nlm.nih.gov/33586003/

 (2018) , , . , . , -1,901,815 , , 2004-2013. , 258 1,032 . , (7% 0.1%), (34.1% 3.2%), (53% 2.3%) (33.7% 2.8%). , 5 (82.2% 86.6%) 2 . .

https://www.ncbi.nlm.nih.gov/pubmed/30027204

 (2018) (ESMO), . , , . , , , . , , , . . , . 
. , . :
' , .
.
, . , . 
, FODMAPs . 
3, .
, , . 
, .  
https://academic.oup.com/annonc/article/29/Supplement_4/iv126/5041967

 (2018) CALM ( : Managing Cancer And Living Meaningfully) -  . ( , ), : , , , . 

305 , 2012 -2016 : CALM (-3 ) . 6 . PHQ-9 0 -27, 5-9 , 10-14 , 15-19 20 . -CALM 3 6 . PHQ-9:

 

 

CALM

7.45

7.41

 

3

5.97

7.01

1.09, p=0.04

6

5.35

6.64

1.29, p=0.02

, -CALM. . CALM .

https://www.ncbi.nlm.nih.gov/pubmed/29958037

( 2015) .

(EPIC) 1,095 28 -29 .

4 (NLCS), 383 .

, , 4 , .

, - , , -20% . 

http://www.ncbi.nlm.nih.gov/pubmed/2660793

( 2016) . .

, 220 281 - .

: " " ( ), " " ( ) " " ( , , ).

" " -88% , .

http://www.ncbi.nlm.nih.gov/pubmed/27206698

( 2015) '. 719 3 .

89% , 78% , 54% -45% .

60 .

, 20% , 17% , 17% , 15% , 15% , 4% -5% .

http://www.ncbi.nlm.nih.gov/pubmed/24745936

 ( 2017), , . - ( ), .

38 , 11 , -5 . (Propranolol) - (etodolac).

. . . 

https://www.ncbi.nlm.nih.gov/pubmed/28490464

 (2017) . 280 - , , - , - ( , , / ), ( , ).
560 , . , , 2 3 . 2.5 5 . , 5.68 , 2.17 4.57 . -68% . , , , . 
:

  1. , 1:2, .
  2. , , . 
  3. () . 

https://academic.oup.com/jnci/article/110/1/djx145/4064136/Use-of-Alternative-Medicine-for-Cancer-and-Its

 (2021) , (EPIC), . 
-45 . :

  1. : , , , , , , , , . 
  2. : , , C, K, D, , , , , . 
  3. : -, , . 
  4. : , , BMI .

:

  • , , - , ( C, D K2), . 
  • , ( ).

EPIC .

https://pubmed.ncbi.nlm.nih.gov/34959845/

( 2017), , .

. , 46 240 ( 100 ), .

92,295 50-79, 14.6 9,565 (, , , , , , ).

, , BMI . , -10% . , , -10-18% , .  .

, .  
https://www.ncbi.nlm.nih.gov/pubmed/28826845
(Singapore Chinese Health Study) . , ( 2017), 63,257 , 45-74 1993-1998. -40 , " . , . 
2014 1,994 . , -15% . - ( 3 ).
https://www.ncbi.nlm.nih.gov/pubmed/28542077

, (2019) , , Oncology Association of Naturopathic Physicians, . . 

: : , , . 99 , .

  • (52.5%) , , , . 
  • , : , D, , , C, , , , .
  • : -, , -,
  • : , , , . 
  • : , , , . 

, . 

: : , , . , . 44 ( 12.5%), -American Board of Naturopathic Oncology. 

-. 

: , , 3, D, , , , , , -

- , - . 

, , . 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769230/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142094/

 ( 2017) , , ( ). , , , . Ras, , , , . , Fructose 1,6-bisphosphate, .  
https://www.ncbi.nlm.nih.gov/pubmed/29030545

 ( 2016) , - - - EGCG, , , , ', .  
https://www.ncbi.nlm.nih.gov/pubmed/26667209

,  ( 2017), 2013 -20 . -8 : ( ), ( , ), , , , , ( , ). 
, . , -38% -33% 2013 . (23% -13% ), (5% / 5%), (5% / 4%) (5% / 3%). , , . , -16,700 -41,200 -20 .
https://www.ncbi.nlm.nih.gov/pubmed/28983918

( 2018), - . -26 -120,000 . 4 , -, EDIP ( : empirical dietary inflammatory pattern), . 2,699 .

EDIP ( 100,000 ) 113 -80 , 151 -92 . , -38 -12 , , , , -. -44% -22% ( -32% ).

-, , , . , - . , , . , -, , .  
https://www.ncbi.nlm.nih.gov/pubmed/29346484

,  ( 2018), Staphylococcus epidermidis . 

https://www.ncbi.nlm.nih.gov/pubmed/29507878

 ( 2018) . 74 , 6 10 ( -4 0-10). 21 . , ( microcrystalline cellulose), 2 .

, -29% FSI ( : Fatigue Symptom Inventory) , -39% MFSI ( : Multidimensional Fatigue Symptom Inventory) .

, 21 , , 23% -35% . .

https://www.ncbi.nlm.nih.gov/pubmed/29426869

(2017) .

, , , . , . , , , , . , , , '-, , -,

, , , .

https://www.ncbi.nlm.nih.gov/pubmed/28501232

(ACS guidelines) 3.

: 1) ; 2) ; 3) , . 992 , 60 , 1999-2001, 2016-2017. 0-6, -6 , 0-8 , . -7 , 335 -299 ( 43 ). 0 1, 5 6 -42%. , (6 8) -51%. , .

-5 85% 76% , -9% . -5 .

https://www.ncbi.nlm.nih.gov/pubmed/29710284

 

 ( 2017) .

4,349 , . , 16.4% , 45.3% .

(64%), (22.1%), (15.1%), (8.1%), (7.3%) (5.8%). , . , .

. . 

https://www.ncbi.nlm.nih.gov/pubmed/28150122

 

, ( 2018) - , . 18 -, 298 , 21 , -, , , 2 .

, (29%) , , , , , . , ( 1) – – ( 2) – .

, , . 

https://www.ncbi.nlm.nih.gov/pubmed/29566200

, ( 2017)  , 216 , .

, -60% , (68% ), (Panax ginseng) .

, , , . , -BMI.

https://www.ncbi.nlm.nih.gov/pubmed/28453297

, -, ( 2017) - - , .  

https://www.ncbi.nlm.nih.gov/pubmed/28304343

 ( 2017) , -324 " ().

, -72 , :

, ,

(Trametes versicolor) -63% , - -45% -49% .

, 26% , (Viscum) B (12%) ,  C (12%), artesunate (7%) (4%).

1600$ 1 6200$ 4, -21% .

https://www.ncbi.nlm.nih.gov/pubmed/27230757

,( 2017)  , .

, -1,000 . , : , , . 41% , 63% ( ) . 335 - , 28% .

, 24% - -85% , . , .

: , .

https://www.ncbi.nlm.nih.gov/pubmed/28252553

,( 2018)  -195 , . , 28% 2006-2016, - .

https://www.ncbi.nlm.nih.gov/pubmed/29860482

, ( 2018)  (ASCO), (SIO) .

, , , , , , , , , . -, . , :

  • : , , .
  • : , , , .
  • : .
  • : .
  • -- .
  • -. 

https://www.ncbi.nlm.nih.gov/pubmed/29889605

 

 |   |  |   |   

 

-  

 

 (2019) 80,110 -. , (n=52,225, 38.3%). (n=27,763, 1.8%) (n=17 692, 1.2%) (n=14 524, 1.0%) / . , (45-64 ) / ( , ) , / .

https://www.ncbi.nlm.nih.gov/pubmed/31360907

-, (2019) , , 229 , 229 . :

https://www.ncbi.nlm.nih.gov/pubmed/30713028

- ( 2015) . 2,041 2,100 . " " , .

-33% , . , , .

, , , ( ) .

http://www.ncbi.nlm.nih.gov/pubmed/26689397

- ( 2016) .

1,905 2,413 .

-48% ( ). , SCC -12 .

.

http://www.ncbi.nlm.nih.gov/pubmed/26944871

,(2020) -8,000 45 ", , .  

https://pubmed.ncbi.nlm.nih.gov/32556069/

, (2018) 15 1935-2014, -1 1 " 3.9% 16%, ,   - -20 .

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2687388

 ( 2017) .

-45,000 , (" "). 1991, 27-44, 4 . 1998, 33-52, . , . -22 1,477 .

40% , . , , , , , , .
https://www.ncbi.nlm.nih.gov/pubmed/28249935

( 2016)    IVF.

19,158 , IVF 1983-1995 -5,950 1980-1995. 2013 53.8 -IVF -55.3 . . -21 839 -109 .

-IVF , 55 3.0% -IVF 2.9% .

-45% 7 IVF , 1-2 . , -23% ( -4 4 ).

IVF . 

http://www.ncbi.nlm.nih.gov/pubmed/27434442

( 2016) -50,000 -14 .  

http://www.ncbi.nlm.nih.gov/pubmed/26997498

( 2016) ( , , , ).

-135,000 ".

5 -, ( 2 ), BMI 18.5-27.5 75 150 .

-28,000 , 4 , ,107,000 , .

* 25% -33% 48% 44% . .

20-40% . 

* :  (population-attributable risk) / . 

http://www.ncbi.nlm.nih.gov/pubmed/27196525

- ( 2016) .

6,814 -6 -10 , COPD, , , - .

, (153%), (170%), (197%), - COPD,  (271%) (429%).

" ". 

http://www.ncbi.nlm.nih.gov/pubmed/26970999

( 2016) 2006-2014 10 , ,

http://www.ncbi.nlm.nih.gov/pubmed/26811140

( 2016) .

, . 
: , , , , .

.

, , . 
, , 50 4-7, , , 1.5. 
7 , .  5.8% . .

http://www.ncbi.nlm.nih.gov/pubmed/27442501

( 2016)   ,
, -, , ( ), O .

, , .

, . 

http://www.ncbi.nlm.nih.gov/pubmed/27461582

, " (2016) . " 89 -17.5 -77,000 .

3 , ( ), .

, , .  

http://www.wcrf.org/sites/default/files/Stomach-Cancer-2016-Report.pdf

( 2017), -3,000 , - , - .
https://www.ncbi.nlm.nih.gov/pubmed/28535255

( 2016) -10 .

1992 -32,000 -3 - 20-29, 40-49 .

18 3,839 . -21 , 4-7 20-29 -19% -22% 40-49. , . 

http://www.ncbi.nlm.nih.gov/pubmed/27033442

(single nucleotide polymorphisms) ( 2016).

, 17,171 -19,862 5,879 .

, , -24 -68 .

, , , .

BRCA .

, 30 80 11.3%, , 4.4% -23.5%.

(, , ), (BMI , , ) .

.

http://www.ncbi.nlm.nih.gov/pubmed/27228256

 ( 2016) . 2-4 , . , , . , Actinomycetes.

BCG ( : Bacillus Calmette–Guérin) Actinomycetes , . , Actinomycetes .

, . 

https://link.springer.com/article/10.1007%2Fs10654-016-0213-z

 ( 2017) . -17 (3 -14 -), (Epidemiology of Endometrial Cancer Consortium).

8,981 , 17,241 . -11% , , 6-9 . , -BMI .
https://www.ncbi.nlm.nih.gov/pubmed/28486362

,  ( 2017), , - , - . 
https://www.ncbi.nlm.nih.gov/pubmed/28092946

, (EPIC), ( 2016) ( ) 10 . -450,000 , -12.8 .
, :

  1. :

Diet Quality Index International (DQI-I), Healthy Eating Index 2010 (HEI-2010), WHO Healthy Diet Indicator (WHO HDI),Healthy Lifestyle Index (HLI).

  1. :

WCRF/AICR guideline score for the prevention of cancer, Dietary Approaches to Stop Hypertension (DASH).

  1. :

Mediterranean Diet Score (MDS), relative Med diet score (rMED), Mediterranean Style Dietary Pattern Score (MSDPS), Healthy Nordic Food Index (HNFI). 

 

, – HLI BMI, , BMI, .
10 15,200 , 3,761 -7,475 . , . , , , BMI, , , , , -12-25% , -16-24% , -9-22% . 
, , . 
https://www.ncbi.nlm.nih.gov/pubmed/27409582

 ( 2017) (ASCO) , , ( , , , , )
, , :

  1. .
  2. , .
  3. .

, , . , .
https://www.ncbi.nlm.nih.gov/pubmed/29112463

( 2017), , -43% . . .  
https://www.ncbi.nlm.nih.gov/pubmed/29205339

,  ( 2018), -DNA , . 
https://www.ncbi.nlm.nih.gov/pubmed/29323295

 ( 2018), , . , - .

-100,000 , -6 1,775 . 20.

, . . , . -20 , .
https://www.ncbi.nlm.nih.gov/pubmed/29360812

( 2018), , , - . -450,000 30-79, ( 2004) . -9 , 1,731 .

, , - .  15 , 5 -15 . 2 .

, . . 
: , . .
https://www.ncbi.nlm.nih.gov/pubmed/29404576

 ( 2018), -400,000 8.7 , , , , .
https://www.ncbi.nlm.nih.gov/pubmed/29386192
https://www.medscape.com/viewarticle/892089?src=wnl_edit_tpal&uac=205542DG

 ( 2018), , . -105,000 43 , -3,300 . NOVA .

, , , , , , , , . , .

, 10% 11-12% . . 
https://www.ncbi.nlm.nih.gov/pubmed/29444771

- ( 2018) - BMI, , - .

31 , , . NMIBC ( : non-muscle invasive bladder cancer), -29% -82% , .

BMI . . .
https://www.ncbi.nlm.nih.gov/pubmed/29430510

, ", ( 2018) .

, 1976, -120,000 30-55 ( ) , 1986, -50,000 40-75 ( ). 4 2010. 794 , 2,223 SCC ( : squamous cell carcinoma) -17,556 BCC ( : basal cell carcinoma) -736, 1,756 -13,092 , , . 
. , , -16% -SCC -6% -BCC. , 6 3 -BCC . . 
https://www.ncbi.nlm.nih.gov/pubmed/29636341

( 2018), .

-32,000 , -17 . , -4 : , , . 462 , 335 (172 -119 ) -152 .

, -14% -23% , . , -44% . . , . 
https://www.ncbi.nlm.nih.gov/pubmed/29516512

,(2019)  , -, - 1% 1.4% . 5 -10 . 

https://www.ncbi.nlm.nih.gov/pubmed/30917803

 (2017) - ( , ). -195 1990-2017. , 25. 2017 11 (22% ) -255 (15% ) . , . , , 3.

, , - , . .

.

https://www.ncbi.nlm.nih.gov/pubmed/30954305

 (2019) " . , . , 20.

  • -80,000 , 5.2% " 2015. , 4.4% -0.82%
  • , . 
  • -5% , (1.8%) (1.2%), (1%). , . 
  • , 45-64 .

https://www.ncbi.nlm.nih.gov/pubmed/31360907

 

-

 

- (2020) BMI , . , , " ". ,

2,071 ( ) 70 -10 . - BMI , : ( 5%), (5-10%) ( 10%). 

:

  • , -44% 60 .

  • , , . 

  • BMI , . 

, , .    

https://pubmed.ncbi.nlm.nih.gov/32889525

, (2020) , BMI 17 . 2,458,170 , 1967-2010. 26,353 -29,488 . 

( -BMI 5 49):

  • -BMI. 

  • -26%. 

  • , . , , -27%. 

  • , BMI ( -85) 10 . . 

  • -BMI , -BMI 5.1% -5.7% .  

, BMI . BMI .  

https://pubmed.ncbi.nlm.nih.gov/32027851/

( 2016) -50,000 -14 .  

http://www.ncbi.nlm.nih.gov/pubmed/26997498

( 2016) , , (HbA1c), (CRP), .

, , .
2,413 , , 27-70 . 24 , 4 .

-13 -36% 13 .

. , HbA1C .

, .

: .  

http://www.ncbi.nlm.nih.gov/pubmed/27032109

 ( 2017), .

243 , 5-6 " ( 3,500 ) (4 – -2,500 -1,700 ). 16 , , ( DEXA) , - ( MRI), . 
, SHBG ( : sex hormone binding globulin), ; -; CRP - IL-6 - ( - IL-6 ).

, , .  
https://www.ncbi.nlm.nih.gov/pubmed/28512158

( 2015) 3,754 .

. BMI .

(BMI 40), . -. 

http://www.ncbi.nlm.nih.gov/pubmed/26385214

( 2016)   . , -74,000 , BMI 3 .

( " " ). , , , , , , , , , .

-7% 10 (5% -17% , ). . , .  

http://www.ncbi.nlm.nih.gov/pubmed/27529652

    ( 2017) ,  .

36,794 50-79, 3 . -3 : ( 5% ), ( 5%) ( 5%) "" " " . 11.4 , 566 .

, -29% . , . ( 4.5 ") , .  

https://www.ncbi.nlm.nih.gov/pubmed/28165909

 ( 2017) .

143 , - . , BMI , , , -, C .

, BMI , , , C . , .
https://www.ncbi.nlm.nih.gov/pubmed/28168180

 ( 2017) - , .

204 - -36 . , : , , , , , , , , , . .
https://www.ncbi.nlm.nih.gov/pubmed/28246088

"  (2017), , ,
, -2012 1.7 , . 119 -12 -260,000 . 
:
: , (18-30) ( . ) ; : .  
: ( - ER negative), , ,
:
: ( ), 18-30; : , , .  
: ( - (ER negative,
" :

  1. : 12, 55, - 30.
  2. , .
  3. .  

" , , .
http://www.aicr.org/continuous-update-project/breast-cancer.html

( 2016) (IARC) . 2013-2014, , 10.8% , 14.9% -5.0% (BMI>30).

, . 2002, : , , , ( ) .

, -1,000 , 8 : , , , , , , () . , -3 : , () .

. , - .  

http://www.ncbi.nlm.nih.gov/pubmed/27557308

( 2016) - 22,000 -22,000 LDL .  

http://www.ncbi.nlm.nih.gov/pubmed/26992435

  . , ( 2013) , . (12% ) (60% ). , , . , . , .

http://www.ncbi.nlm.nih.gov/pubmed/24156623

 (2020) , , . 

https://pubmed.ncbi.nlm.nih.gov/33301708/

( 2016)
( -) .

. PDAC .

, , - - PDAC

http://www.ncbi.nlm.nih.gov/pubmed/27246539

( 2016) .

.

PlGF/VEGFR-1 .

(TAM), , VEGFR-1 -.

PlGF -.

http://www.ncbi.nlm.nih.gov/pubmed/26861455

( 2016)  

http://www.ncbi.nlm.nih.gov/pubmed/26756352

- ( 2017) ( , , , , , , , , ).

, 18,688 -24,751 62 -63 . -12 1,656 .

- BMI, , - ( -11%, 13%, 9% -15%, , ). , -BMI, , -16%, 21%, 15% -20%, . , , . 
, .
https://www.ncbi.nlm.nih.gov/pubmed/28441380

 (2017) (CDC) ( ) 2005, . 
https://www.cdc.gov/mmwr/volumes/66/wr/mm6639e1.htm?s_cid=mm6639e1_e

 ( 2017) . -175 -12 , 2012 (BMI 25) 10 .

-5% 2012 2002, -627 793 . , 24.5% -38.4% .

, 2 . , 26.1% -31.9% 1980-2002. , .
http://www.thelancet.com/journals/landia/article/PIIS2213-8587(17)30366-2/fulltext

 

 

-

 

( 2016) , , (HbA1c), (CRP), .

, , .
2,413 , , 27-70 . 24 , 4 .

-13 -36% 13 .

. , HbA1C .

, .

: .  

http://www.ncbi.nlm.nih.gov/pubmed/27032109

 ( 2017) .

143 , - . , BMI , , , -, C .

, BMI , , , C . , .
https://www.ncbi.nlm.nih.gov/pubmed/28168180

 ( 2017), 1998-2010, 2 -30% , . ( 2) 55, .
https://www.ncbi.nlm.nih.gov/pubmed/28436468

 ( 2017) . -175 -12 , 2012 (BMI 25) 10 .

-5% 2012 2002, -627 793 . , 24.5% -38.4% .

, 2 . , 26.1% -31.9% 1980-2002. , .
http://www.thelancet.com/journals/landia/article/PIIS2213-8587(17)30366-2/fulltext

 

 

-

 

( 2016), , . , .
2003-2009, 6 , 58,148 , 39,183 , , 775 .

, ( + ) , 2.74 -5.4 , 3.74 15 .

53% , 13% 59% . 
, , . 

http://www.ncbi.nlm.nih.gov/pubmed/27467055

( 2016)   . , -74,000 , BMI 3 .

( " " ). , , , , , , , , , .

-7% 10 (5% -17% , ). . , .  

http://www.ncbi.nlm.nih.gov/pubmed/27529652

"  (2017), , ,
, -2012 1.7 , . 119 -12 -260,000 . 
:
: , (18-30) ( . ) ; : .  
: ( - ER negative), , ,
:
: ( ), 18-30; : , , .  
: ( - (ER negative,
" :

  1. : 12, 55, - 30.
  2. , .
  3. .  

" , , .
http://www.aicr.org/continuous-update-project/breast-cancer.html

 

 

-

 

24 ( 2016) 

http://www.ncbi.nlm.nih.gov/pubmed/26836587

-, (2019) , , 229 , 229 . :

https://www.ncbi.nlm.nih.gov/pubmed/30713028

Shenling Baizhu San (: SBS) . 10 : Panax ginseng, Atractylodes macrocephala, Wolfiporia extensa, Glycyrrhiza glabra, Dioscorea opposite, Dolichos lablab, Nelumbinis Nucifera, Coix lacryma-jobi, Amomum, Platycodon grandifloras.

( 2015), ,

http://www.ncbi.nlm.nih.gov/pubmed/25897964

 

 

 

 |   |   |   |  3  | 

 

-

 

 

-  (2020) . 27 , - , , , 2. 15 -108 . 

, , -BMI . - 35 .  . 

https://pubmed.ncbi.nlm.nih.gov/32444054/

- ,(2020)  . 17 - -. 

:

  • : - , -6% 12% , -3% 20% 15-90 /. 

  • , , , . 

  • . , . , - - 90 / -6% . ( ) ( ), . 

, . , .  

https://pubmed.ncbi.nlm.nih.gov/33297391/

- , (2021) . 17 , -11 -. 

, -34% . , ( -35%), . , 18 / -45% . 

, ergothioneine, - . 

, . 

https://pubmed.ncbi.nlm.nih.gov/33724299/

 (2021) . , -FDA: , , , . , - . 

, , . 2, ,

, (ADI). , . 

http://www.biotech-asia.org/vol18no2/artificial-sweeteners-and-their-health-implications-a-review/

 (2020) . -129 , , EBSCO, , , (Apitherapy) . , . 

:

  • -18 , -39 , -17 .

  • – 18 , -6 -3 , . 

  • – 39 , (6 ) (3 ), / . 

  • – , .

  • , , . , , , , , .

. , , . 

https://pubmed.ncbi.nlm.nih.gov/32507447/

 (2019) - (Luteolin) . 

https://www.ncbi.nlm.nih.gov/pubmed/30798142

(2019)  – (, ) ( ).
https://pubmed.ncbi.nlm.nih.gov/30639116/

 (2019) , . , - , , (, - ), , , .
https://www.ncbi.nlm.nih.gov/pubmed/31146462

 (2018) - , , , , EGCG, , .

https://www.ncbi.nlm.nih.gov/pubmed/30424557

 (2020) . , 2 , . - , , , , . 

101,279 18 (42 ), -6 . 92.8 , -20% , ( ) 55.57 / ( ) 135.31 /. 19.48 -62.23 /, .

-17%   , -51%. 

. , , ( , ), , , , . 

, , ( ).  

https://pubmed.ncbi.nlm.nih.gov/32936868/

, (2019) , – , 100% - . 101,257 18 (42 ). , 2-15 . -5 , 2,193 , 693 , 291 -166 . 90.3 " -74.6 " , 45% , 36% -19% . 

, ( 18% 100 "/) ( 22% 100 "/). -12%. 

, , . 

https://www.ncbi.nlm.nih.gov/pubmed/31292122

 (2018) (EPIC), . , . 471,495 , -15 49,794 ( 12,063 , 6,745 -5,806 ). , , , , , , , /// -100 . , , .

-7% , 81.4 69.5 -10,000 , . , , , . .

https://www.ncbi.nlm.nih.gov/pubmed/30226842

- ( 2016) .

, 5,145 4,097 .

-26% . . , , 1-2, 2-2.5 2.5 -22%, 41% -54%, .

.
: (NIH). .

http://cebp.aacrjournals.org/content/25/4/634.full.pdf+html

( 2016) . .

, 220 281 - .

: " " ( ), " " ( ) " " ( , , ).

" " -88% , .

http://www.ncbi.nlm.nih.gov/pubmed/27206698

( 2015)    (Fagopyrum esculentum) 

, ,  , , -, - - - .

- , D-chiro-inositol, , . 

http://www.ncbi.nlm.nih.gov/pubmed/26270637

 (2018) - (). , . 

(Emblica officinalis), , , . , , - : , Polyalthia longifolia HCD , Prodigiosin ( , " ). , - - . . 

https://www.ncbi.nlm.nih.gov/pubmed/28671583

( 2015) . , .

http://www.ncbi.nlm.nih.gov/pubmed/26467752

 (2018) , . -9 , , , -500,000 . , 10 . 

57 -78% ( , ). 14,225 . . , 1, 1, 2-3, 4-5, 6-7, 8 -6%, 8%, 12%, 12%, 16% -14% . , , . , , . , , . 

" - -NIH

https://www.ncbi.nlm.nih.gov/pubmed/29971434

- ( 2017) , , .

18 , 2 -2,905 , 8 - 1,825 -4,652 . -2 -35% , - ( 29% 67%). , , , 2, B C. , , -2 -14% . 
, , , , ; - , -DNA; (); 2. 
, .
https://www.ncbi.nlm.nih.gov/pubmed/28490552

 ( 2017), , . 15,950 55 .

3,340 (20.4%) (nonadvanced), 1,643 (10%) (advanced) 189 (1.2%) .

. , . . .
https://www.ncbi.nlm.nih.gov/pubmed/28468894 

, ,
. -500,000 -10 . -16 , 41,693 . , ( 3 ) ( -12% -7% ). . ( -60% -40% ). , , -22% , -30% -30% . - -15,000 CRP . , . 
. , 1993-1996 ' , -185,000 -, , . -16 , 58,397 . , -12% 1 , 18% 2-3 -18% 4 . , . , 55 . , , , ,

, , , ( ). , , , , , , , . . , . , , - . , .

 https://www.ncbi.nlm.nih.gov/pubmed/28693038

https://www.ncbi.nlm.nih.gov/pubmed/28693036

( 2017), , .

-93,000 , 1995-1998 2012. 2,482 . , , : (" "), . , , , , , . , , , , , , , . , , .

-15% , , . . . . .
https://www.ncbi.nlm.nih.gov/pubmed/28526274

 (2017), (AICR) (WCRF), .

, 2007, 99 ( ) - -29 -250,000 . , ( ), , (-500 '/), , , , , . , , - C, , D -, ( -100 ) ( ) . 
- , , , , , , , 3 , , , , , , , , , , A, B6, E, , , -, , , . 
-47% , . 
http://www.aicr.org/continuous-update-project/colorectal-cancer.html

- ( 2017), 631 879 , ( ) -22% , . , .
https://www.ncbi.nlm.nih.gov/pubmed/28742092

 ( 2017) , , ( ), Fructose 1,6-bisphosphate Ras, . 
https://www.ncbi.nlm.nih.gov/pubmed/29030545

- ( 2017), , ( ). 128 256 - .

, , -67% - , , , -BMI. , -91% . , -65% , .  
https://www.ncbi.nlm.nih.gov/pubmed/29124385

 ((2017) - . , " , -49,000 50-79. ( , ) ( ) 7-12 .

46,200 , 9 92 -165 . , -14% . -, , (BMI 25), . - . 
https://www.ncbi.nlm.nih.gov/pubmed/28922784

 ( 2017) , . , .

-87,000 40-69, -17 1,668 . , , . , SCC ( : small cell carcinoma), 3.5 5 .

, SCC.
https://www.ncbi.nlm.nih.gov/pubmed/29151475

 ( 2017) , . , , , .

1,334 , . 8 137 . 4 , 0-3 , -73% . , BMI , BMI 27 3 . .  
https://www.ncbi.nlm.nih.gov/pubmed/29105845

(2020) . , . 

91 , , . -BMI, . : ( 1.5 /"/) ( 1.5 /"/). -30% , 2.2 /"/ 0.8 /"/ . 

– 14.7 7.3 . , , , , , , , , BMI, , . 

.

https://pubmed.ncbi.nlm.nih.gov/32919817/

 

 

-

 

 (2019) . , . , . 

, 3 (, ) -, -24%, 49% -65%, . -. , , . -, , .

https://www.ncbi.nlm.nih.gov/pubmed/31504082

 (2018) - (Punica granatum) , , , . 

https://www.ncbi.nlm.nih.gov/pubmed/29729421

- ( 2015) PSA ( ) .

183 1.6 ( 2 ).

PSA, -11.1 - 15.6 -12.9 -14.5 .

, MnSOD AA , (1.8 12 ).

http://www.ncbi.nlm.nih.gov/pubmed/26169045

 (2016) - , . 

https://www.ncbi.nlm.nih.gov/pubmed/26829056

( 1) (Vitis rotundifolia) ( 2015).

14 , 500-4,000 ", -.

4,000 " .

6-30 .

4 . 6 ( ), .

PSA -5.3 ( , p=0.17), . 2 (500 ") (4,000 "). 

: . . 

http://www.ncbi.nlm.nih.gov/pubmed/26012728

- (2021) . 

, ": 66,719 (1984-2014) -42,016 (1986-2014). , , . 33,898 . 

, , , . , , , . , , -13% , -12% , -10% , -35% . 

, - -26 , 1,892,885 -145,015 . , -13% . , . . 

, .    

https://pubmed.ncbi.nlm.nih.gov/33641343/

- ( 2016) - , , .

http://www.ncbi.nlm.nih.gov/pubmed/27339168

    ( 2017), .

-200,000 , 9-15 17,681 . .

, , . . -3 " , , .  
:    . 

https://www.ncbi.nlm.nih.gov/pubmed/28142032

( 2015), 300,000 ( ) ,

http://www.ncbi.nlm.nih.gov/pubmed/26607934

, - ( 2016) -1,500 -1,500 . - -

http://www.ncbi.nlm.nih.gov/pubmed/26791185

( 2015) , , .

, , .

22 ( ) 21 14 (7 , -50 ). .

, , (p<0.01) * (p<0.05) . , - (genotoxicity) (p<0.01).

, . 
* , , .

http://www.ncbi.nlm.nih.gov/pubmed/26428278

 (2019) , - . 56,048 , 23 14,083 . 

, . -500 "/ , . -, ( -20 /) - ( 20 /).

, , . 

https://www.ncbi.nlm.nih.gov/pubmed/31409784

( 2016) . -90,000 27-44 1991 -44,000 13-18 1998.

2013 3,235 , .

, -3 -25% -0.5 , . .

, , . , - .

, .

.

.
:  - - (, , , ) - (, , , , , ).

http://www.ncbi.nlm.nih.gov/pubmed/27170029

    ( 2017), .

-200,000 , 9-15 17,681 . .

, , . . -3 " , , .  
:    . 

https://www.ncbi.nlm.nih.gov/pubmed/28142032

( 2016), -46,000 23 , (TMPRSS2:ERG-positive), . 

https://www.ncbi.nlm.nih.gov/pubmed/26817504

- (2017)   ,  , .

142 , 95 -2 . 200 -8%, -16% , -8% , -3% -10% . . , 800 (10 ), .

, , , , . , , 5.6 2013 500 , 7.8 800 .

, .  

https://academic.oup.com/ije/article/3039477/Fruit

 ( 2016) -   , , , ,

https://www.ncbi.nlm.nih.gov/pubmed/25872898

 ( 2016) 8 , .
https://www.ncbi.nlm.nih.gov/pubmed/26753515

 ( 2017) - . 
https://www.ncbi.nlm.nih.gov/pubmed/28488765

( 2015) -  Allium,   (Allium cepa) ,   .

  , . , - .

   .

http://www.ncbi.nlm.nih.gov/pubmed/25586902

( 2014) - , , -

http://www.ncbi.nlm.nih.gov/pubmed/24984103

(2014) , , , ,

http://www.ncbi.nlm.nih.gov/pubmed/25250322

, , .

, - - .

( 2015) - , , , , EGCG, , , '' .

.

http://www.ncbi.nlm.nih.gov/pubmed/25693744

( 2016) .

5 , . , diethylnitrosamine (DEN). .

http://www.ncbi.nlm.nih.gov/pubmed/26865652

( 2015) - docetaxel

http://www.ncbi.nlm.nih.gov/pubmed/26200777

(2015), - -

http://www.ncbi.nlm.nih.gov/pubmed/25624761

( 2015)  (Petroselinum crispum) - -DNA,

http://www.ncbi.nlm.nih.gov/pubmed/25582089

( 2015) - (Betanin), , . 

http://www.ncbi.nlm.nih.gov/pubmed/26463240 

(2015) - . 

http://www.ncbi.nlm.nih.gov/pubmed/26320438

 ( 2016) . 
https://www.ncbi.nlm.nih.gov/pubmed/27120393

 ( 2017) - ( ) . 
https://www.ncbi.nlm.nih.gov/pubmed/28528091

, - ( 2017), C .

49 -1,105 1,449 . , , -34% -, 30% -, 35% -, 25% -26% C.

, C . , .
https://www.ncbi.nlm.nih.gov/pubmed/28293540

,  ( 2017), , , .
https://www.ncbi.nlm.nih.gov/pubmed/28698610

 ( 2017), ", , . -470,000 -12 2,453 , 1,165 -1,297 .

( ) 438-4211 "/ ( ) 0-84 "/. , , -24% . . .
https://www.ncbi.nlm.nih.gov/pubmed/28724656

 ( 2016) ' (Lycium barbarum) . 
https://www.ncbi.nlm.nih.gov/pubmed/26525080

 ( 2018) .

192 -173 " (), 0 3, 2006-2012.

(, , ), ( , , ), , , .

0 431 -865 /, , . , , 24 / -49% -57%, . , , .

, ( 33 /) ( 70 /) -50% . , -. https://www.ncbi.nlm.nih.gov/pubmed/29230660

 

-

 

-90,000 ( 2016)

http://pediatrics.aappublications.org/content/early/2016/01/28/peds.2015-1226

- ( 2016) . 14 (48,052 ), (16,882 ), (19,489) (1,092 ).

, -19% -18% .

, . . 

http://www.ncbi.nlm.nih.gov/pubmed/27193606

 ( 2016) - , Avemar. .
https://www.ncbi.nlm.nih.gov/pubmed/27245162

 ( 2016) , , . 
https://www.ncbi.nlm.nih.gov/pubmed/27941714

 ( 2017) , . , ", 1,575 1-3. 6 -4 . 8 , 773 , 174 .

, , 5 -22% -14% . , . . . 
https://www.ncbi.nlm.nih.gov/pubmed/29098294

 ( 2017) , - .
https://www.ncbi.nlm.nih.gov/pubmed/28605975

 

 

-

, (2019) Annals of Internal Medicine, . , . , . , , , .

:

  • , . , , 48,835 . , ( ). 
  • -105 , -6 , , , - .
  • , , 2 ( 12 1000 10 ).
  • , , , , . 
  • , , , .

, - WHO, , , . 

: , , , . . , 2, , . , , , , .
, , , , .

https://www.ncbi.nlm.nih.gov/pubmed/31569235

https://www.ncbi.nlm.nih.gov/pubmed/31569236

https://www.ncbi.nlm.nih.gov/pubmed/31569217

https://www.ncbi.nlm.nih.gov/pubmed/31569213

https://www.ncbi.nlm.nih.gov/pubmed/31569214

https://www.ncbi.nlm.nih.gov/pubmed/31569219

 (2021) ", , . , , . 102,521 , 1993-1998, 2017. 25,976 . 

:

  • -9% , -12% , -21%

  • -6% -14%, , .

  • , , -12%, 24% -11%, , .

  • -10% . 

  • -20% , -15% -14%, . 

  • , , , , , . 

https://pubmed.ncbi.nlm.nih.gov/33624505/

- ( 2016) , , D -. 490 656 - . , , , , - , .  , -, . ( ) ( 1200 " -49% 478 " ), D . , 23 -29% -6 . , , -. 

https://www.ncbi.nlm.nih.gov/pubmed/27632371

, , . 1,854 , 321 . -50% . , . , -. , . .  

https://www.ncbi.nlm.nih.gov/pubmed/27595916

659 699 ( 2015) , . 

http://www.ncbi.nlm.nih.gov/pubmed/26551148

(2015) - . : , C -E.

, , .

-, . . , , , , , . , .

  . . 

http://www.ncbi.nlm.nih.gov/pubmed/26156538

( 2016) , , , , , .

6 , 100 ( -11% , 15% , 17% -19% ), .

50 (4% , 8% , 9% , 18% , 19% , 13% , 22% , 24% , 32% ).

, , , .

, , . , .  

https://www.ncbi.nlm.nih.gov/pubmed/27597529

( 2017) . , .

, -18,000 - 9.4 . , (38% ) (13-14% ) -7% -14%, , . squamous cell -small cell carcinoma. , -8% .

5% 16-17% squamous cell -small cell carcinoma. . , .
https://www.ncbi.nlm.nih.gov/pubmed/28742456

 (2021) , , . 521,120 50-71 ". 16 129,328 , 38,747 . 0 -28.7 -2,000 , . 118.3 -330 " -2,000 . 

, . , -7% , 300 / -19% , -16% -24% . 63.2%, 62.3% -49.6% , , , . , , , . , , , , , . 

, , . , . . 

, . .   

https://pubmed.ncbi.nlm.nih.gov/33561122/

 

 

- 3

 

( 2016), 3 1,659 .

3 , 0.3 3 -40% , 0.1 3. , 3 0.15 -70% 3. 3 .

3 .  

http://www.ncbi.nlm.nih.gov/pubmed/27436272

( 2015) - - -3 , . 

http://www.ncbi.nlm.nih.gov/pubmed/25684599

 ( 2016) .  

https://www.ncbi.nlm.nih.gov/pubmed/27996158

 ( 2016) . 
https://www.ncbi.nlm.nih.gov/pubmed/27455311

 ( 2018), , . 826 - 3 - . 6.5 , 2 , -42% -57% . , . .  

https://www.ncbi.nlm.nih.gov/pubmed/29489429

 

 

-

- (2019) , , . (>18). , , , , , , , , , , , , , , , , , . : , . 23 , , 19 , 1 , 1 -1 ; , 12 . 

  • 10% (p=0.02).
  • .

  • (p=0.03), , (p=0.90). 
  • , -, . 
  • 20% (p=0.008). 
  • 10 " -7% (p=0.003).

: 

  • (p<0.001), (p<0.001) (p=0.003). 
  • (p=0.04). 
  • 10 " 9% (p=0.02). 
  • (p=0.02). 
  • 5 12% (p<0.001). 
  • (p=0.61).
  • .

,

https://www.ncbi.nlm.nih.gov/pubmed/31278047

( 2016) , . -48,000 30-49. -19 206 , ( ) .

, .  

http://www.ncbi.nlm.nih.gov/pubmed/27010988

, -.

, ( ), , , , , 2 , , . , , ( ).

, - .  
:  . : http://www.naturopedia.com/article.asp?rId=880

https://www.ncbi.nlm.nih.gov/pubmed/27723080

, ( 2017), ', , ( ) - , ' .

 https://www.ncbi.nlm.nih.gov/pubmed/28148690

 ( 2017) . - .

-27,000 , . 11.5 , 2,598 , 287 .

, ; -91% , -51% ', -80% -67% . . 

: , . 
https://www.ncbi.nlm.nih.gov/pubmed/29114854

- ( 2018) . 30 , -270,000 - -21,000 . .

, , -30%, 10%, 16% -35%, . , . , . 
https://www.ncbi.nlm.nih.gov/pubmed/29300347

 ( 2018) .

192 -173 " (), 0 3, 2006-2012.

(, , ), ( , , ), , , .

0 431 -865 /, , . , , 24 / -49% -57%, . , , .

, ( 33 /) ( 70 /) -50% . , -. https://www.ncbi.nlm.nih.gov/pubmed/29230660

 

 

 |   | 

 

-

 

-  ( 2017) - .

-62,000 55-69, 1986 -20 . -.

2,321 1,665 , - 40% (ER-). (ER+) . 
, - . , , -6% , -2% , -27% -23% . -
https://www.ncbi.nlm.nih.gov/pubmed/28260236

- ( 2016)  - .

, 100 , , , . - .

. - , ( -29%, 57% -30%, ).

- -14% (13 ) (4%, 3 ) (9%, 9 ).

,  , . , , , , .

, , 2 .  

http://www.ncbi.nlm.nih.gov/pubmed/27428849

( 2015)   -   , -. , - .

, , , , , .

, , , , , , .

- . , - .

http://www.ncbi.nlm.nih.gov/pubmed/27014505

- ( 2017), , , . , , -754 1,277 - 38-85. , : -, (prudent) .
, - - , , - -34% ( -6) -51% (cT2b-T4). . , .  
https://www.ncbi.nlm.nih.gov/pubmed/28842246

 

, (2019) , - . 67,332 45-60 1990. 1993, -. 1993-2008 2,003 , 404 , 1,367 , -232 .

- , -17% . , ( -28%) ( -23%), .

- , .

https://pubmed.ncbi.nlm.nih.gov/31380561

 

-

 

-,  (2020) . 20 -, 34 , : , B12 , , , , , , . 

:

  • , , LDL -HDL. 

  • , , , , . 

  • , , . 

  • , B12 , .  

, B12.

https://pubmed.ncbi.nlm.nih.gov/32204974/

-26,000 ( 2015) -35%

http://www.ncbi.nlm.nih.gov/pubmed/26561618

( 2016), , . -11,000 55-69 ( 1986), -5 (, , , 2-5 , 6-7 ).

-20 279 , 312 -399 . , .

, -75% . , .  
: , .
, , .

http://www.ncbi.nlm.nih.gov/pubmed/26931668

,  (2017), . IL-6 .

IL-6 , , - . , , IL-6 , , .

, -, , . 
https://www.ncbi.nlm.nih.gov/pubmed/28193578

 (- 2017), 233 236 ,
- 818 935 , " " ( , /, , , ) . , " " ( , ) . " " ( , ) " " ( , , ') - . , ( ) .
.
https://www.ncbi.nlm.nih.gov/pubmed/29017525
https://www.ncbi.nlm.nih.gov/pubmed/28898273

 

 

-

 

- ( 2015), , - - .

, .

, - - -, .

- .    

http://www.ncbi.nlm.nih.gov/pubmed/26631612

177 ( 2016) 10-18 25-29.
: .

http://www.ncbi.nlm.nih.gov/pubmed/27197283

( 2017) . , .

, -18,000 - 9.4 . , (38% ) (13-14% ) -7% -14%, , . squamous cell -small cell carcinoma. , -8% .

5% 16-17% squamous cell -small cell carcinoma. . , .
https://www.ncbi.nlm.nih.gov/pubmed/28742456

 

 

-

 

- ( 2018) .

44 , (1,082,092) , (dietary inflammatory index-DII). , 45 ( , , , , , ), - -.

-58% , . , DII 8.3% .

, , , , , . , . 

https://www.ncbi.nlm.nih.gov/pubmed/29566194

 

 

 

- (2021) , . 11 1,066 , 77% , 14% , 4% , 4% -1% . 
, . , . . 
, .
https://pubmed.ncbi.nlm.nih.gov/34649267/

-  (2021) , (fast-mimicking diet – ), . 31 , -22 , . 

(12 ), ( ), ( ), ( ) ( ). 22 . , - . , . 

, , .  

https://pubmed.ncbi.nlm.nih.gov/33359756/

 (2019) . :

  • 45 , , -10-20% , , , , , , .  

  • 18 -, 40-50% , , . 

  • - -25 . 

. , .  

https://pubmed.ncbi.nlm.nih.gov/31095082/

( 2016) .

  • , -1.4 " , . 10-27 -187,000 , , -13 : , , , , , , , , , , , . , . , .
  • 9 . 8,309 12,612 . -34% .
  • - . 128 512 . , 2.5 . 

, - .  

http://www.ncbi.nlm.nih.gov/pubmed/27183032

http://www.ncbi.nlm.nih.gov/pubmed/27197285

http://www.ncbi.nlm.nih.gov/pubmed/27105330

( 2016) -9 . 8,309 12,612 . 

-34% . 

, . 

( 2016) -12 6,806 5 . 

-22-34% .

http://www.ncbi.nlm.nih.gov/pubmed/27197285
http://www.ncbi.nlm.nih.gov/pubmed/27299959

- ( 2017) : , , . - 113 , 11,525 , 1999-2016.

, - (p<0.001), . , , - . .
https://www.ncbi.nlm.nih.gov/pubmed/28253393 

( 2016) , , . 

12 , 10-61% . 

, 19-60% , 23-60% - 27-52% . .

http://www.ncbi.nlm.nih.gov/pubmed/27340121

, , , , , , , . 

https://www.ncbi.nlm.nih.gov/pubmed/24282099

 (2020) , , . , . , , 3,718 , 4,248 , -69,860 .  

, (MVPA), . -22.5 MET (MET = , /), . 

:

  • , , . 

  • , . 

  • , . 

, , , 150-300 75-150 . 

https://pubmed.ncbi.nlm.nih.gov/33079415/

"  (2017), , ,
, -2012 1.7 , . 119 -12 -260,000 . 
:
: , (18-30) ( . ) ; : .  
: ( - ER negative), , ,
:
: ( ), 18-30; : , , .  
: ( - (ER negative,
" :

  1. : 12, 55, - 30.
  2. , .
  3. .  

" , , .
http://www.aicr.org/continuous-update-project/breast-cancer.html

( 2016) (IARC) . 2013-2014, , 10.8% , 14.9% -5.0% (BMI>30).

, . 2002, : , , , ( ) .

, -1,000 , 8 : , , , , , , () . , -3 : , () .

. , - .  

http://www.ncbi.nlm.nih.gov/pubmed/27557308

-  ( 2017) .

160 , 208 766 , " (Roswell Park Cancer Institute) 1989-1998 . , , -4 " ".

-77% -73% . . , .  
https://www.ncbi.nlm.nih.gov/pubmed/28528291

 (2019) . 

, , , , , . , . , , , , . 

, , . , . . – , , , - .  

https://pubmed.ncbi.nlm.nih.gov/31617590/

 (2020) . 54,686 30, , . , , , , , , , - . 

, , – :

  • .

  • .

  • .

  • – 14 21 .

  • – 14-35 -21-49 .

  • – 35 49 . 

– 7.5 MET / -15 MET / (MET = , /). 

, -46%, -39% -62%, . , -7.5 MET / ( -25%, -21% -52%, ). 

https://pubmed.ncbi.nlm.nih.gov/32406936/

 ( 2017) , .

299 57 . - 7 (), . , .

. , . ,
https://www.ncbi.nlm.nih.gov/pubmed/28677009

 (2019) . 7.5-15 MET ( - /) . , , -15 , 7.5, 15, 22.5 30 MET . 755,459 , -10 50,620 . 

  • , ( -8-14% ), ( -6-10%), ( -10-18%), ( -11-17%), ( -14-19%), ( -18-27%), ' ( -11-18% ). 
  • , . 
  • -BMI, -BMI. 

.

https://pubmed.ncbi.nlm.nih.gov/31877085/

 (2017) . 150 75 , .

-140,000 -70 . -13 , -43,000 . ( ), -26% 2-6 ( ) -20% 6 -22% . , .

, , . 
http://www.ajpmonline.org/article/S0749-3797(17)30460-9/fulltext

 ( 2018) , CT - , - .

3,241 , 2000-2013 2 3. -6 . , 34% () -37% ( ).

, -41% . , ( ) -35% ( ). , 89%. . BMI . , CT .
https://www.ncbi.nlm.nih.gov/pubmed/29621380

,( 2018)   (COSA), , .

.

:

  • , . 
     
  • - ; 150 -2-3 - .
     
  • (best practice) . 

, , .

, , . , .

https://www.ncbi.nlm.nih.gov/pubmed/29719196

 ( 2018) ,

-, - .

48 , 3,632 55 , . -, .

. , -30 . " 44 - , - , .

, 11% . . 

, .

15,450 " , 21 - 1970-1999 - 2013. 26 , , " " (metabolic equivalent task –MET - /, MET -3.5 , . - MET , / ). 

-10 , 1,063 (811 , 120 -132 ). 11.7% MET 0 , 8.6% 3-6 , 7.4% 9-12 -8% 15-21 . , , .

8 ( 5,689 ), 8 MET 40% . , , .

https://www.ncbi.nlm.nih.gov/pubmed/29894274

https://www.ncbi.nlm.nih.gov/pubmed/29862412

,(2020) , T . 

https://pubmed.ncbi.nlm.nih.gov/33095157/

 

 

 

- (2021) . - , ,

11 429 18. ( ) ( ), , . 

, , . , , .  

https://pubmed.ncbi.nlm.nih.gov/33964406/

-, (2021) (MBSR) . " 1,318 , . ( - Insomnia Severity Index, Pittsburgh Sleep Quality Index), , , , . 

, MBSR , . ( , CBT , ), MBSR , . 

MBSR , . 

https://pubmed.ncbi.nlm.nih.gov/33460741/

-,(2019) 17 1,111 , .   

https://pubmed.ncbi.nlm.nih.gov/31855257/

 (2020) . , 464 . . 

:

  • .

  • (skeletal traction). 

  • ( , , ). 

, .   

http://www.sciencedirect.com/science/article/pii/S0965229920318203

 (2020) (BRR - Benson's Relaxation Response) , . . 84 , . , 5 . . 

24 -48 , . . 

-BRR , .   

https://www.sciencedirect.com/science/article/abs/pii/S0965229919314876

( 2016) .

322 : 6 .

(, , ) ( ) 6 6 .

, , .

https://www.nlm.nih.gov/medlineplus/news/fullstory_159172.html

 (2019) , 303 18 . , . . 

: (1) (2) (3) . 

57.8 (23.1-82.3). : 

(n=95, 31.4%), (n=43, 14.2%), (13.9% ,n=42) (n=37, 12.2%).

, 149 (53.8%) . (54.5%, n=165), ( (n=272, 89.8%) (n=145, 47.9%).

:

  • , 56% (n=171) , 115 (38%) , -5.6% (n=17) .
  • (72.4% 48.8%, p=0.045). 
  • (p=0.003). 
  • , (p=0.076) (p=0.064). 
  • , , .

, . , .

https://www.ncbi.nlm.nih.gov/pubmed/31274335

,(2020)  , , . 8 10-17. 60 4 , . , , . 

. , . . , .

https://pubmed.ncbi.nlm.nih.gov/31987232/

240 ( 2014)

.  

http://www.ncbi.nlm.nih.gov/pubmed/25090913

( ) (2019) (MBSR) . . -25 , 20 . 2.5 , 4.5 , . , . 16 . , - 8 . 75%. . , . 

, . 

https://pubmed.ncbi.nlm.nih.gov/31780005/

121 ( 2016)

http://www.ncbi.nlm.nih.gov/pubmed/26853501

, , , , , , , . 

https://www.ncbi.nlm.nih.gov/pubmed/24282099

" ( 2017), , ,
1990-2015, : 

  • /: , , .
  • / : , , , .
  • : .
  • : .

, , , , ,
" -- , . , . 
, -, . , .
https://www.ncbi.nlm.nih.gov/pubmed/28436999

, (2019) 380 , ( ) , . 
https://pubmed.ncbi.nlm.nih.gov/31519267/

 ( 2017) ( 1-3) .

(74 ) (68 ) 4 -3 6 - . , , (85 ). , , 3, 6 -12 .

. , , . ( ) , . , 3 -6 , . .
https://www.ncbi.nlm.nih.gov/pubmed/28940301

 ( 2017), , . , .

30 , . -, 1-2 (20 ) (30-40 ). , 105 -11 . , . 28 , 20 , 7 -1 .

20 1 2, 2 12 , 8 3-4 12 . 93% . , . 
https://www.ncbi.nlm.nih.gov/pubmed/28150504

 

 

 |   |   |   | ' |   |   |  |   |  |   |   |   | 

 

 

 (2020) -, , . 16 1,650 . 

-, , , , . - . - / . , .  , - , (APC) , . , , , - .     

https://pubmed.ncbi.nlm.nih.gov/33309412/

 (2020) , , ( ). 29 , -15 (9 ). 12 71 : (Achillea millefolium), (Allium sativum), (Aloe vera), (Matricaria (Chamomilla) recutita), (Calendula officinalis), (Curcuma longa), (Glycine max), '' (Zingiber officinale), (Mentha x piperita), (Plantago major).

:

  • '' , 6 '' , 6 . 
  • ''
  • , , , ,
  • (MicrSoy-20) . 
  • ( ).

:

  • , . , . 
  • , .
  • (), , , . 

, .

https://pubmed.ncbi.nlm.nih.gov/32147034/

- ,(2020) (Aloe vera). 20 , 10 , -10 -.  , , GERD, , , , , . , , . - " 94 14,352 , -82% -18% . 71 . , 47 , (). , , , ,

https://pubmed.ncbi.nlm.nih.gov/32924222/

 (2022) - , . , .  : , , , (Calendula officinalis), , , (Aloe), Hangeshashinto , '' (Zingiber officinale), ' (Panax ginseng) .  , , . , .     

https://pubmed.ncbi.nlm.nih.gov/34709682/

 (2021) , . 

https://pubmed.ncbi.nlm.nih.gov/33559280/

 (2021) , -, , (Mentha spicata), -, , , . 

https://pubmed.ncbi.nlm.nih.gov/34087400/

, (2020) , , . , . , , - . 

, . 14 , , 78 . . , , .

(Matricaria recutita), (Salvia officinalis), (Calendula officinalis) (Thymus spp) . , . 

https://pubmed.ncbi.nlm.nih.gov/31955287/

 (2020) - (Purpurin), (Rubia cordifolia), , .  

https://pubmed.ncbi.nlm.nih.gov/33254282/

 (2019) - 16 , .   

https://pubmed.ncbi.nlm.nih.gov/31464060/

 (2019) (Moringa oleifera), (-).

https://www.ncbi.nlm.nih.gov/pubmed/30241049

 (2019) .

https://www.ncbi.nlm.nih.gov/pubmed/31294509

 (2018) - (Moringa oleifera) , , ,

https://www.ncbi.nlm.nih.gov/pubmed/29534518

 ( 2017) .

. , .

149 , 26 (17.4%) , , 4 (2.7%) . 2.5 (p=0.03).
, 149 , 84 (56.4%) -, 75 (50.3%) 122 . , . : (Allium sativum), (Aloe barbadensis/capensis), (Annona muricata), (Camelia sinesis), (Echinacea angustifolia), - (Ginkgo biloba), (Matricaria recutita), (Moringa oleifera), ' (Panax ginseng), , (Uncaria tomentosa), (Valeriana officinalis), (Vitis vinifera). , , . , . 
: .
, , . .
https://www.ncbi.nlm.nih.gov/pubmed/28628392

( 2016) , (Serenoa repens), - . 
27 , , 960 ", . , 21 , 22 .

(IPSS) ( ) . , 2 11 0 10 .

960 " .

http://www.ncbi.nlm.nih.gov/pubmed/26891611

- ( 2015) '' .

60 5 '' .

'' . , , .

http://www.ncbi.nlm.nih.gov/pubmed/26051575

, (2018) , Liu Jun Zi Tang , (). .

, . 8 : (Atractylodes macrocephala), (Pinellia ternata), (Citrus reticulata), (Ziziphus jujube), (Poria cocos), (Glycyrrhiza glabra), ' (Panax ginseng) '' (Zingiber officinale). , .

https://www.ncbi.nlm.nih.gov/pubmed/29690597

- ( 2015) , Goshajinkigan, . 11 : Rehmannia glutinosa, Achyranthes fauriei, Cornus officinalis, Paeonia suffruticosa, Alisma plantago-aquatica, Dioscorea japonica, Dioscorea opposite, Plantago asiatica, Wolfiporia extensa, Aconitum carmichaelii, Cinnamomum cassia.
182 mFOLFOX6 (: , ) 7.5 3 . 2 50.6% -31.2% .

http://www.ncbi.nlm.nih.gov/pubmed/25627820

- ( 2015) .

56 . 15 " 4 14 , .

( 2.39 -1.07 7 -0.32 14 ). , ( 2.39 -2.75 7 -2.89 14 ). . 

http://www.ncbi.nlm.nih.gov/pubmed/25667123

- ( 2015) - (Cynara scolymus)  ( / ).

http://www.ncbi.nlm.nih.gov/pubmed/26136339

- ( 2015) Dehydroandrographolide, (Andrographis paniculata), . 
https://www.ncbi.nlm.nih.gov/pubmed/26356821

- ( 2015) . 22 -2,300 . -15 , -7 -3 .     , .

 http://www.ncbi.nlm.nih.gov/pubmed/25698710

( 2015) - .  , . : ( ); ( Artemisia); Baicalin -Baicalein ( Scutellaria baicalensis); ( Berberis); ( - Betula papyrifera), ( Capsicum); ( Curcuma longa); ( ); ( , ); EGCG ( Camellia sinensis); ( Acacia greggii); ( Trifolium pratense); (  Vitis vinifera); ( ); Gambogic Acid ( Garcinia hanburyi); ' ( ' Panax); Glycyrrhiza uralensis, ( Gossypium hirsutum); ( Terminalia chebula); (Magnolia);  ( ); Oridonin  Rabdosia rubescens;  ( ); Phenethyl-isothiocyanat ;  ( Vitis vinifera);  ( ); Sanguinarine ( Sanguinaria Canadensis); ( Silybum marianum); - Thymoquinone ( Nigella sativa); ( Cornus officinalis).

http://www.ncbi.nlm.nih.gov/pubmed/25875508

( 2015) . 8 , " 798 .  . .  : Astragalus membranaceus, Angelica sinensis, Paeonia japonica, Atractylodes ovata, .

http://www.ncbi.nlm.nih.gov/pubmed/26275657

 ( 2017) - .
, (Gemcitabine), 3,3-Diindolylmethane , Thymoquinone (Nigella sativa), Cucurbitacin B, , - sulforaphane, , Dimethylaminoparthenolide - (Tanacetum parthenium) -Piperlongumine (Piper longum).
, , . 
, . , , , ', , . : , wogonin ( ), apigenin -chrysin . 
- (Ginkgo biloba), (Curcuma longa), (Viscum album) '. Huang-Qin-Tang PHY906 , : (Scutellaria baicalensis), (Glycyrrhiza uralensis), (Paeonia lactiflora) (Ziziphus jujuba).
https://www.ncbi.nlm.nih.gov/pubmed/28232946

 ( 2016), , .

- . , -, , , [ (Silybum marianum)],  Phytol ( ), (Glycyrrhiza glabra), (Scutellaria baicalensis) Baicalein, (Coix). , PHY906 : Scutellaria baicalensis, Glycyrrhiza uralensis, Paeonia lactiflora, Ziziphus jujube. 

https://www.ncbi.nlm.nih.gov/pubmed/26879574

 (2016) - , , , PEITC ( -Phenethylisothiocyanate) , Aloe Emodin [ (Aloe vera)] , - Dioscin ( Dioscorea villosa), , , . 
https://www.ncbi.nlm.nih.gov/pubmed/26791479

 ( 2017) . 21 ( ), . , , , -. , , . , '' (Zingiber officinale), 0.5-1 . (Mentha piperita) (Mentha spicata) . 
. , .  
https://www.ncbi.nlm.nih.gov/pubmed/28193133

 ( 2016) , . : (Withania somnifera), (Tribulus terrestris), (Asparagus racemosus), (Azadirachta indica), (Ocimum sanctum) '' (Zingiber officinale). 
https://www.ncbi.nlm.nih.gov/pubmed/27681646

( 2015) . . . , , , , EGCG ( ), , , , ''

http://www.ncbi.nlm.nih.gov/pubmed/26503998

( 2015) -  Allium,   (Allium cepa) ,     , . , - .    .

http://www.ncbi.nlm.nih.gov/pubmed/25586902

( 2015) . , , . 22 (Paullinia cupana) (Ganoderma lucidum) .

, . 

http://www.ncbi.nlm.nih.gov/pubmed/25811312

( 2016) . fisetin, EGCG, , , , , , , , -3- .

http://www.ncbi.nlm.nih.gov/pubmed/26864554

( 2015)  . -. EGCG, , , , -, ', . - .   

http://www.ncbi.nlm.nih.gov/pubmed/26184171

( 2015) -  (Phyllanthus emblica), .

http://www.ncbi.nlm.nih.gov/pubmed/26180601

( 2015) - 6 -. :  rottlerin  Mallotus philippensis;  berbamine (Berberis);  sparstolonin B Sparganium stoloniferum;  sulforaphane ()  ;  plumbagin  Plumbago zeylanica  (6)-shogaol '' (Zingiber officinale). - . . , .

http://www.ncbi.nlm.nih.gov/pubmed/26695359

( 2015)   .

. , , . , . , . , -. , , ; . , , , .  

http://www.ncbi.nlm.nih.gov/pubmed/26325482

( 2015)   , ' (Panax ginseng), , ,   (Camellia sinensis), ' , (Allium sativum), , ''

http://www.ncbi.nlm.nih.gov/pubmed/26651248

( 2015) - ( - HCC).

ALT -HCC. , ALT . , - HCC. : Sho-saiko-to, Juzen-taiho-to, SNMC (Scutellaria baicalensis) ' '. - HCC. 

http://www.ncbi.nlm.nih.gov/pubmed/26457019

 ( 2016) - , (, , , , ), . 

https://www.ncbi.nlm.nih.gov/pubmed/27057273

 ( 2016) - - (Olea europea).

, , , . - -DNA. , NF-κB , . .
https://www.ncbi.nlm.nih.gov/pubmed/27548217

, , , , , , , . 

https://www.ncbi.nlm.nih.gov/pubmed/24282099

 (2022) (Achillea millefolium) , . 39 . , , , . , -. . .  

https://pubmed.ncbi.nlm.nih.gov/35430924/ 

(- 2015) . -397 . , - 28% , 22% -22% (92%) .

34% , - Urtica dioica (-22% ), Foeniculum vulgare (- 20% ) (10%).

52% -38% .

, .

http://www.ncbi.nlm.nih.gov/pubmed/26465625

- (2016), , (Yerba mate) 60% .  

https://www.ncbi.nlm.nih.gov/pubmed/27039789

( 2015) .

. , -16 . 339 (80.3%), 44 -3 , (Urtica dioica), (Allium sativum), (Nigella sativa) (Curcuma longa) .

-29 .

, -15 , P450. : Allium sativum, Camellia sinensis, Curcuma longa, Foeniculum vulgare, Ginkgo biloba, Hypericum perforatum, Matricaria recutita (chamomilla), Melissa officinalis, Mentha piperita, Panax ginseng, Polygonum, Silybum marianum, Thymus vulgaris, Trifolium pratense, Vitis vinifera.

18 , :  Allium sativum, Camellia sinensis, Cuminum cyminum, Curcuma longa, Ferula asafetida, Foeniculum vulgare, Ginkgo biloba, Hippophaerhamnoides, Linum usitatissimum, Nerium oleander, Nigella sativa, Olea europaea, Panax ginseng, Thymus vulgaris, Trifolium pratense, Trigonella foenum-graecum, Vitis vinifera, Zingiber officinale.

-7 :  Curcuma longa, Ganoderma lucidum, Linum usitatissimum, Nigella sativa, Panax ginseng, Silybum marianum, Viscum album.

, .

:  , , . , , .
. , .

http://www.ncbi.nlm.nih.gov/pubmed/26599199

( 2014) (Holoil®) (Hypericum perforatum) (Azadirachta indica) .

28 ( , ) .

, .

http://www.ncbi.nlm.nih.gov/pubmed/25544371

(2015), Network pharmacology, "Triphala", , , . 

https://www.ncbi.nlm.nih.gov/pubmed/26477351

( 2015) -.

. , .

2,439 - -3,575 - (, , ).

- 492 .

-.  

http://www.ncbi.nlm.nih.gov/pubmed/26074488

( 2015) , ,

http://www.ncbi.nlm.nih.gov/pubmed/26047758

 (2021) , .  

https://pubmed.ncbi.nlm.nih.gov/34230130/

 (2021) EGCG, EGCG p53 -DNA .  

https://pubmed.ncbi.nlm.nih.gov/33579943/

( 2014) Cyclophosphamide

http://www.ncbi.nlm.nih.gov/pubmed/25595312

 (2018) (Allium sativum) , , . 

https://www.ncbi.nlm.nih.gov/pubmed/29621132

( 2015) , , , " ( ). 

http://www.ncbi.nlm.nih.gov/pubmed/25695860

( 2015)

http://www.ncbi.nlm.nih.gov/pubmed/25962735

( 2014) -

http://www.ncbi.nlm.nih.gov/pubmed/25005066

( 2015) gemcitabine

http://www.ncbi.nlm.nih.gov/pubmed/25672620

( 2015) .

http://www.ncbi.nlm.nih.gov/pubmed/26087719

( 2015) - (Smilax Glabra). 

http://www.ncbi.nlm.nih.gov/pubmed/25732255

( 2015)

http://www.ncbi.nlm.nih.gov/pubmed/26176704

( 2015) - . 

http://www.ncbi.nlm.nih.gov/pubmed/26204945

( 2015) - (Olea europaea)  . 

http://www.ncbi.nlm.nih.gov/pubmed/26193251

(2015) - (Melissa officinalis) , , . 

http://www.ncbi.nlm.nih.gov/pubmed/26320439

(2015) - (CRUEL) . (Piper Nigrum), (Glycyrrhiza glabra), (Moringa Oleifera) (Ocimum sanctum). 

https://www.ncbi.nlm.nih.gov/pubmed/26745095

( 2015) (Trifolium pratense) . .

https://www.ncbi.nlm.nih.gov/pubmed/26530625

  (Moringa oleifera) .

https://www.ncbi.nlm.nih.gov/pubmed/27074620

( 2017), , , .

, , . 98 , 42 . , : (Triticum aestivum), (Viscum album), '' (Zingiber officinale), (Ephedra campylopoda) (Viscum cruciatum). .

'' - . , , , '', . , '' . .

, , .

https://www.ncbi.nlm.nih.gov/pubmed/28238155

 ( 2016) (Salvia miltiorrhiza) (ROS).
https://www.ncbi.nlm.nih.gov/pubmed/27579153

 ( 2016) - . (Scutellaria barbata), (Lobelia chinensis), (Solanum nigrum) -Hedyotis diffusa, - .

- (p<0.01) - Hedyotis diffusa . . temozolomide. 
https://www.ncbi.nlm.nih.gov/pubmed/27843296

 ( 2015) - (Ziziphus Jujube) . 
https://www.ncbi.nlm.nih.gov/pubmed/26718441

 ( 2015) , , .
https://www.ncbi.nlm.nih.gov/pubmed/26667771

 ( 2016) (Lepidium meyenii) -, .
https://www.ncbi.nlm.nih.gov/pubmed/27681649

( 2014) '     (cisplatin).

(). , ' 50 " " . ' .

http://www.ncbi.nlm.nih.gov/pubmed/25495691

- (Astragalus membranaceus) 500 "/"

https://www.ncbi.nlm.nih.gov/pubmed/26719057

 ( 2016), , (5-)
60 , , . 
4 30 - . , , -15 " (Salvia officinalis) (Thymus vulgaris) (Mentha piperita). 0-4, . 4-7 5 14 .

70% (10% 1 -20% 2), 40% (53.3% 1 -6.7% 2), p=0.001. -14 , (93.3% -96.7%). .
https://www.ncbi.nlm.nih.gov/pubmed/27515877

 ( 2016) 85, 4. 5 , , : (Codonopsis pilosula), (Astragalus membranaceus), (Atractylodes macrocephala), (Poria cocos), (Scutellaria barbata), (Salvia miltiorrhiza) (Prunella vulgaris).

, , .
https://www.ncbi.nlm.nih.gov/pubmed/26597286

 (2016) (Anorexia Cancer Cachexia Syndrome), , , , .
https://www.ncbi.nlm.nih.gov/pubmed/27758689

 ( 2017) - (Salvia officinalis) (Salvia miltiorrhiza) . 
https://www.ncbi.nlm.nih.gov/pubmed/27930987

 (2016) '' (Zingiber officinale) (doxorubicin). 150 , '' 500 " 3 , .
1-3 3 . . , '', . , 85 (doxorubicin60 mg/m2 + cyclophosphamid 600 mg/m2), '' ( 0.64 1.13, p<0.05). '' , -. , '' .  
: .  
https://www.ncbi.nlm.nih.gov/pubmed/27644633

 ( 2017) -50 (Hypericum perforatum) (Azadirachta indica) . 
https://www.ncbi.nlm.nih.gov/pubmed/28101834

- (2016) - 3 : (Ganoderma lucidum), (Lentinus edodes) (Grifola frondosa). 
https://www.ncbi.nlm.nih.gov/pubmed/28008808

 ( 2017) - ( ) . 6 : Rhus verniciflua, (Ulmus rubra), (Polygonatum Sibiricum), ' (Lycium chinense), (Ganoderma lucidum) ' (Panax ginseng). 
https://www.ncbi.nlm.nih.gov/pubmed/27626609

,  (2017), . . , , . , . , . - (STAT3, mTORC1, AMPK). .

https://www.nature.com/articles/s41698-017-0024-z

 (2017) Thymus alternans ( ) , - . 
https://www.ncbi.nlm.nih.gov/pubmed/28222613

 ( 2016) Aurora A kinase, . , San Huang Decoction, , (Rheum spp) (Coptis chinensis).
https://www.ncbi.nlm.nih.gov/pubmed/27461831

( 2016), , .

, 466 , 2000-2010, : .

-70%, . : (Salvia miltiorrhiza), (Astragalus membranaceus), (Dioscorea villosa), (Rehmannia glutinosa) (Glycyrrhiza glabra). 
https://www.ncbi.nlm.nih.gov/pubmed/26773538

 (2016) . , , . , , , , . , , , , . , : + , + EGCG, + (Corydalis ambigua), (Scutellaria baicalensis), (Ganoderma lucidum) .
https://www.ncbi.nlm.nih.gov/pubmed/26638885

 ( 2016) , , - , . 
https://www.ncbi.nlm.nih.gov/pubmed/27347927

 ( 2017) (Stevia rebaudiana), , -, , , . 
https://www.ncbi.nlm.nih.gov/pubmed/28792778

 ( 2016) (Urtica spp) () .
https://www.ncbi.nlm.nih.gov/pubmed/27090648

 ( 2017) (Melissa officinalis) , . 
https://www.ncbi.nlm.nih.gov/pubmed/28259690

 ( 2017) - - , - - .
https://www.ncbi.nlm.nih.gov/pubmed/28799775

 ( 2016) (Capsicum annuum) , , , . 
https://www.ncbi.nlm.nih.gov/pubmed/26756096

 ( 2017) - (Moringa Oleifera) , , ,

https://www.ncbi.nlm.nih.gov/pubmed/29144438

 ( 2016) (Cinnamomum zeylanicum) , Sanyangxuedai, , . 
https://www.ncbi.nlm.nih.gov/pubmed/27706567

 ( 2016) - (Nigella sativa), thymoquinone ( ), .
https://www.ncbi.nlm.nih.gov/pubmed/28476718

 ( 2016) (Serenoa repens) - . 
https://www.ncbi.nlm.nih.gov/pubmed/27527161

 ( 2017), , . , . 30 , . -, 1-2 (20 ) (30-40 ). , 105 -11 . , . 28 , 20 , 7 -1 . 20 1 2, 2 12 , 8 3-4 12 . 93% . , . 
https://www.ncbi.nlm.nih.gov/pubmed/28150504

- ( 2017), 281 , 39% -54% . (Alium sativum) (Urtica dioica) . , .
https://www.ncbi.nlm.nih.gov/pubmed/28573249

 ( 2017), , . 184,386 20-79 - . -13 1,853 . (-80%).

1.73 10,000 , 0.85 10,000 -0.63 Si Wu Tang [ (Rehmannia glutinosa), (Paeonia spp), ' (Angelica sinensis) (Ligusticum striatum)]. -43% -64%, . , .
https://www.ncbi.nlm.nih.gov/pubmed/28858112

 ( 2016) - - (Rosmarinus officinalis) (carnosic acid, rosmarinic acid) . 
https://www.ncbi.nlm.nih.gov/pubmed/27869665

 ( 2016) - (Cimicifuga racemosa) , .
https://www.ncbi.nlm.nih.gov/pubmed/27223250

 ( 2016) . 17 , 1,224 , .

-10 , -7-15 . , . . 
, (Astragalus membranaceus), (Atractylodes macrocephala), (Codonopsis pilosula) (Poria cocos). .
https://www.ncbi.nlm.nih.gov/pubmed/27490098

 (2017) , -, . , . : (Glycyrrhiza glabra), (Uncaria tomentosa), (Camellia sinensis), ' (Panax ginseng), (Prunus armenaica), (Allium sativum), (Arctium lappa) (Curcuma longa).

. : ajoene, arctigenin, β-carotene, curcumin, epigallocatechin-3-gallate, ginsan, glabridin, quinic acid. .  
https://www.ncbi.nlm.nih.gov/pubmed/27539316

- ( 2017) , . 22 , 9 1,329 ". , - , Karnofsky performance score) KPS): 

, Aidi . Aidi – (Astragalus membranaceus), ' (Eleutherococcus senticosus) Mylabris phalerata. 

. , , , ( ). .

https://www.ncbi.nlm.nih.gov/pubmed/28538415

 ( 2016) . 

https://journals.lww.com/tnpj/Fulltext/2016/11000/Herbal_supplements_used_to_treat_common_chronic.6.aspx

 ( 2017) - (Garcinia) (Hypericum perforatum) .

https://www.ncbi.nlm.nih.gov/pubmed/28363851

 (2019) ", , , , , , , .

https://www.ncbi.nlm.nih.gov/pubmed/30860938

 

 

( 2014) 1-3

(Polyphenon E) , 400 ", 600 " 800 ", 6 . 

HGF (12.7%- 6.3%), . , .

.  

http://www.ncbi.nlm.nih.gov/pubmed/24646362

- ( 2015) . 13 -.

6 , -22% . 11% . 
9 , . , , . 

http://www.ncbi.nlm.nih.gov/pubmed/26138307

( 2015)   . 
- -, . 
EGCG, -. , , , , , , .

, .

http://www.ncbi.nlm.nih.gov/pubmed/26177066

( 2015)   , ' (Panax ginseng), , ,   (Camellia sinensis), ' , (Allium sativum), , ''

http://www.ncbi.nlm.nih.gov/pubmed/26651248

(2016) - , .

3 , -EGCG Ziziphus jujube.

, - ( ) ( ).

https://www.ncbi.nlm.nih.gov/pubmed/26156544

- ( 2017) . ( -) , 400 "/ EGCG 600 "/ 12-30 .

, . , , , , 7 . -60% .

, . 
https://www.ncbi.nlm.nih.gov/pubmed/28353571

, - (2016), - (Camellia sinensis), , .
https://www.ncbi.nlm.nih.gov/pubmed/27221834

( 2015) . .

.

, , , , EGCG ( ), , , , ''

http://www.ncbi.nlm.nih.gov/pubmed/26503998

( 2013) . . . , , . , , , , . 

http://www.ncbi.nlm.nih.gov/pubmed/24172305

http://www.ncbi.nlm.nih.gov/pubmed/24172300

-  ( 2017) PSA , -PSA
22 PSA 4-15 . 12 . 4 100 " , 30 " -100 " , 4 ( -8 ). , . , .

-PSA . , , -PSA, . 

https://www.ncbi.nlm.nih.gov/pubmed/28181675

( 2015) , , , " ( ). 

http://www.ncbi.nlm.nih.gov/pubmed/25695860

 ( 2016) -, , EGCG .
https://www.ncbi.nlm.nih.gov/pubmed/27483305

 ( 2016) -, - (EGCG), -, . , EGCG , , . , , - .

https://www.ncbi.nlm.nih.gov/pubmed/27869750

 (2021) EGCG, EGCG p53 -DNA .  

https://pubmed.ncbi.nlm.nih.gov/33579943/

 

 

 |  | 

 


(2001) 25 . 25 ( 36-77) . , ( ), , ( ), ( ). ( 99.3% ) 500 " -12 . 4 , . , 1 2 , 2 7 () , 1 6 , 1 4 -2 6 . 8 , . 7 25 (28%). .
https://www.ncbi.nlm.nih.gov/pubmed/11712783
(2016) (BCM95–Biocurcumax) . 223 ( – ) 3.6 . 88% -7% . 67.5% -55.3% (p=0.03). 88.9% -87.5% . (p=0.71), (p=0.02). . .
https://www.ncbi.nlm.nih.gov/pubmed27267893
(2010) . 85 PSA 100 " 40 " . , PSA≥10 -PSA (p=0.01). , PSA .
https://www.ncbi.nlm.nih.gov/pubmed/20503397
(2009) (MGUS-Monoclonal gammopathy of undetermined significance). -MGUS -10% . 26 MGUS 2:1 4 ( 3600 ", DMT 320 ", BDMT 80 ") . ( , ) -20 / ( 12-30% ). () () . , 27% -25% ( N-telopeptide of type I collagen ). .
https://www.ncbi.nlm.nih.gov/pubmed/19737963
(2005) (tropical pancreatitis). . . 20 500 " 5 " . ( ) . , . 
https://www.ncbi.nlm.nih.gov/pubmed/16394323
(2006) (Familialadenomatous polyposis). . ( 22-54) ( ) 1440 " 60 " . -60.4% (p=0.043) -50.9% (p=0.039) . . 
https://www.ncbi.nlm.nih.gov/pubmed/16757216
(2011) (ACF-colonic aberrant crypt foci) . 44 2 4 30 . 41 . , - (PGE2, 5-HETE) , 40% (p<0.005). , .
https://www.ncbi.nlm.nih.gov/pubmed/21372035
(2010) DNA . 286 ( ) 25-55 -DNA ROS . . ( 20:1) 2.5 . (p<0.001) -DNA, -ROS (Catalase, SOD, glutathione reductase, glutathione S-tranferase, glutathione peroxidase) .
https://www.ncbi.nlm.nih.gov/pubmed/20056736
(1992) - . 16 1.5 30 . . , . ( AST -ALT) ( ), . .
https://www.ncbi.nlm.nih.gov/pubmed/1579064
(1998) (reverse smoking)*. 1 . 
* .
https://www.ncbi.nlm.nih.gov/pubmed/9863273

 

 (2022) - . -DNA , . - . , , , . , , - , . 

.  

https://pubmed.ncbi.nlm.nih.gov/34697839/

(2015) - , , , , EGCG, , , '' . , , , -DNA. 17 , . . . 
https://www.ncbi.nlm.nih.gov/25693744
(2014) . (solid tumors) ( ) 180 " . (p<0.001) (p<0.001) TNFΑ, (p<0.001) TGFβ, (p<0.001) MCP-1, CRP, (p=0.005) substance P, (p<0.001) CGRP. , (p=0.061) IL-6. , (p=0.012) IL-8.
https://www.ncbi.nlm.nih.gov/pubmed/24648302
(2011) . 126 ( ) 1080 " 10-30 . (p<0.05), (p<0.05) -TNFɑ, p53 (p<0.05) (p<0.05) .
https://www.ncbi.nlm.nih.gov/pubmed/21314329
(2001) . 15 440-2200 " ( -36-180 " ) 2-4 . ( ) . 
https://www.ncbi.nlm.nih.gov/pubmed/11448902
(2008) . 8 , . 21 . : -18 (73%) ( 4-35) (IL-6, IL-8, IL-10 -IL-1). NFkB, Cox2 STAT3 ( ). .
https://www.ncbi.nlm.nih.gov/pubmed/18628464
- (2017) (, , ) PSA , -PSA. 22 PSA 4-15 . 12 . 4 100 " , 30 " -100 " , 4 ( -8 ). , .
-PSA . , , -PSA, . 
https://www.ncbi.nlm.nih.gov/pubmed/28181675
(1987) ( ). 62 ( ) . -90% . -70% , -10% . . . 
https://www.ncbi.nlm.nih.gov/pubmed/2435036
 

 

 

 (2020) , , ( ). 29 , -15 (9 ). 12 71 : (Achillea millefolium), (Allium sativum), (Aloe vera), (Matricaria (Chamomilla) recutita), (Calendula officinalis), (Curcuma longa), (Glycine max), '' (Zingiber officinale), (Mentha x piperita), (Plantago major).

:

  • '' , 6 '' , 6 . 
  • ''
  • , , , ,
  • (MicrSoy-20) . 
  • ( ).

:

  • , . , . 
  • , .
  • (), , , . 

, .

https://pubmed.ncbi.nlm.nih.gov/32147034/

(2014) (Meriva) . 160 35-70 ( 70 ) , , (5-fluorouracil, cisplatin, vinblastine, gemicitabine, CCNU, MOPP/ABVD/COPP) ( 80 ) (80 ). ( 100 " DMT:BDMT:curcumin 1:8:33 -200 " ) 1500 " ( 60 ). 158 (2 ). : , , , , / , , , (p<0.05). , (P<0.022) (p<0.021). : , , , , , , , / , , , (p<0.05). , (P<0.022) (p <0.021). .
https://www.ncbi.nlm.nih.gov/pubmed/23775598
(2013) (severe radiation dermatitis) . 30 ( 58.1) in situ ( ) 6 . ( RDS) (p=0.008). (moist desquamation) (28.6% 87.5%, p=0.002).
https://www.ncbi.nlm.nih.gov/pubmed/23745991
(2013) . 80 ( 400 " -80 " , 10 " ) ( ) / . (p<0.001), (p<0.01) ( , ) (p<0.001).
https://www.ncbi.nlm.nih.gov/pubmed/24165896
(2014) . 60 . (p<0.05).
https://www.ncbi.nlm.nih.gov/pubmed/26182820
(2013) (Curcumall) doxorubicin . ( , 15.2) 20 ( C3 95% '' 0.4%, -330 " ) chlorhexidine 0.2% 21 . . . .
https://www.ncbi.nlm.nih.gov/pubmed/23709456
(2015) , . 17 1 '' (Zingiber officinalis) -1 (Curcuma longa) , 1 " ' (Gentiana lutea) , 14 . 3 '' , '. 20 , 7 14 ; , . , , , . , . . 
https://www.ncbi.nlm.nih.gov/pubmed/25324460

 

 

 | 

 

 (2020) -, , . 16 1,650 . 

-, , , , . - . - / . , . 

, - , (APC) , .

, , , - .     

https://pubmed.ncbi.nlm.nih.gov/33309412/

(2012) (Ganoderma lucidum) , , , . 5 (/) .
- / , ( ) -50% (p=0.02). , . . , ( -T CD3, CD4 -CD8 - 3.91%, 3.05% - 2.02% , p<0.01-0.03). , -NK CD4/CD8 ( -CD4/CD8 , p=0.03).
. . , , . .
. , . .
https://www.ncbi.nlm.nih.gov/pubmed/22696372
(2016) . 373 . , . 1-3 , . . , . , . , -T ( 213 2-4% -T) NK ( 89 , NK ). , , ( ) . , . 
https://www.ncbi.nlm.nih.gov/pubmed/28083078
(2005) . , . (mitogenic reactivity) . 65% . , -* .
* .
https://www.ncbi.nlm.nih.gov/pubmed/16351502 
(2013) . - ( -), ( - - ) , , . : 14-3-3 , MAPK, ERK, AKT, JNK, FAK AP-1 -NFkB, , , , ( MMP-2,9, uPA, VEGF, TGFβ,c-Myc, IL-8), Nrf2 .
https://www.ncbi.nlm.nih.gov/pubmed/23790022
(2004) (Ganoderma lucidum). , NK, T -B. . .
, . (-) .
https://www.ncbi.nlm.nih.gov/pubmed/15525457 
(2015) . , , . 22 (Paullinia cupana) (Ganoderma lucidum) . , .
https://www.ncbi.nlm.nih.gov/pubmed/25811312

 


(2017) (Ganoderma lucidum) . 40 ( ) 2000 " . . (p=0.0024) 8 (p=0.019*). , -TNF (p=0.0004) . , . , ( ).
* -p<0.01.
https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2017-Congress/Ganoderma-Lucidum-has-immunostimulatory-and-antinflamatory-effect-in-breast-cancer-patients-4P
(2012) (Ganoderma lucidum spore) . 48 ( ) . 3 . (p<0.01), (p<0.01) (p<0.05) , . (p<0.01). . . , TNF 6 (p<0.01 - p<0.05 ) . , ( ) . 
https://www.ncbi.nlm.nih.gov/pubmed/22203880
(2010) (Ganoderma lucidum) (Colorectal adenoma). 225 () (123 ) (102 ). 1.5 ( - 14 ) 12 . 96 . . 0.66 , 0.42 (p<0.01). , -1.73 " -1.40 " (p<0.01).
https://www.ncbi.nlm.nih.gov/pubmed/20518254
(2006) . 47 ( 48.4) 3 -4 60 , ( 25% ) 5.4 ( -81 ) 12 . . -41 ( ). CD3, CD4, CD8 -CD56 IL-2, IL-6 -IFNɣ -NK. IL-1 -TNFɑ . . , -T CD4:CD8. , IL-1 -IL-6, IFNɣ, CD3, CD4, CD8 -NK (p<0.05) IL-2 -IL-6, CD8 -NK. .
https://www.ncbi.nlm.nih.gov/pubmed/16428086
(2003) (®Ganopoly) . Ganopoly (Ganoderma lucidum) 25% . 68 . Ganopoly 1.8 ( - 27 )* 12 . ( 35.1% -22.6% , ). , - Ganopoly KPS-Karnofsky performance status ( 10 50% 14.3% , p<0.05). (46.4% -39.3% ) (28.1% -21.9% ).
, -Ganopoly , , , ( 84.4% 42.9%).
, -Ganopoly , -T -NK, - CD4/CD8 ( ) (p<0.05). - Ganopoly . 
* Ganopoly.
https://researchbank.rmit.edu.au/view/rmit:19180
(2005) (Ganopoly) . Ganopoly (Ganoderma lucidum) 25% . 36 3 4 Ganopoly 5.4 ( - 270 )* 12 . 30 , ( – ), T CD3-4-8-56, - IL2, IL-6, (IFN), -NK. (p<0.05). -Ganopoly . 
* Ganopoly.
https://www.ncbi.nlm.nih.gov/pubmed/16117607
(2003) (Ganoderma lucidum) . 34 ( 45-64) 5.4 Ganopoly, 25% ( -270 )*, 12 . 12 -60 . 30 . . , IL-2, IL-6 (p<0.05). -IL-1 - TNF-alpha (p<0.05). . -NK CD56+ ( - 238.3 -277.4, p<0.05), -T CD3+, CD4+, CD8+ CD4/CD8 ( ) . , (80%) -phytohemmaglutinin ( – ) (p<0.05) -NK 34.5% 26.6% (p<0.05), . 20% : (6.7%) (13.3%). 
* Ganopoly
https://www.ncbi.nlm.nih.gov/pubmed/12916709
(cohort) (2012) ' (Ganoderma lucidum) . 4149 36 .
, . 58.8% , 36 36.2%. , , , , . , , . , 36 . (p<0.05) , (p<0.05) . (p<0.001 ). 
https://www.ncbi.nlm.nih.gov/pubmed/22745737
(1992) 48 (, , ) ( ) . , . . . 
175 72.5% . . 
https://www.abebooks.com/Chinese-Medical-Herbology-Pharmacology-John-Chen/16278843054/bd
(2008) ( ) , ( 8-18) * ( 13-18). : (1-50 ) , . ( -100 ) , 50, 100 -200 . , .
* : mercaptopurine-6 , methotrexate -vincristine , methotrexate ( ) -12 .
https://www.ncbi.nlm.nih.gov/pubmed/18603664
* Ganopoly®:
. 25% 600 " ( -30 ). 0.5% , 50:1, 600 " -30 (48,120).
, (119,125) 25% 600 " ( - 9 ). (Alpha Group ) (Cordyceps sinensis, Astragalus membranacus, Trametes versicolor, Lycium chinense, Chitosan).
.
 

 

'

'  | '

 

'

( 2015)   , ' (Panax ginseng), , ,   (Camellia sinensis), ' , (Allium sativum), , ''

http://www.ncbi.nlm.nih.gov/pubmed/26651248

( 2015) - ( - HCC).

ALT -HCC.

, ALT .

, - HCC.

: Sho-saiko-to, Juzen-taiho-to, SNMC (Scutellaria baicalensis) ' '.

- HCC. 

http://www.ncbi.nlm.nih.gov/pubmed/26457019

( 2015) .

. , -16 . 339 (80.3%), 44 -3 , (Urtica dioica), (Allium sativum), (Nigella sativa) (Curcuma longa) .

-29 .

, -15 , P450. : Allium sativum, Camellia sinensis, Curcuma longa, Foeniculum vulgare, Ginkgo biloba, Hypericum perforatum, Matricaria recutita (chamomilla), Melissa officinalis, Mentha piperita, Panax ginseng, Polygonum, Silybum marianum, Thymus vulgaris, Trifolium pratense, Vitis vinifera.

18 , :  Allium sativum, Camellia sinensis, Cuminum cyminum, Curcuma longa, Ferula asafetida, Foeniculum vulgare, Ginkgo biloba, Hippophaerhamnoides, Linum usitatissimum, Nerium oleander, Nigella sativa, Olea europaea, Panax ginseng, Thymus vulgaris, Trifolium pratense, Trigonella foenum-graecum, Vitis vinifera, Zingiber officinale.

-7 :  Curcuma longa, Ganoderma lucidum, Linum usitatissimum, Nigella sativa, Panax ginseng, Silybum marianum, Viscum album.

, .

:  , , . , , .
. , .

http://www.ncbi.nlm.nih.gov/pubmed/26599199

 ( 2016), , ' (Panax notoginseng) - . 
https://www.ncbi.nlm.nih.gov/pubmed/27222068

(2015) -  '  

http://www.ncbi.nlm.nih.gov/pubmed/26107240

 ( 2017) ' (Panax ginseng) , , .
https://www.ncbi.nlm.nih.gov/pubmed/28068835

 (- 2016) ' (Panax), -. ' , , , , , , , . ' .

- ', -. , , , , . , ' , . , ' .
https://www.ncbi.nlm.nih.gov/pubmed/28039696

'

 (2018) ' (Panax ginseng).

https://www.ncbi.nlm.nih.gov/pubmed/27643558

'

 |  |   | 

 

( 2013) - ' , .
, ' , .
- .
http://www.ncbi.nlm.nih.gov/pubmed/24133965

 


( 2017) 6 , , ' 7 . ' . -Rb1 , -Compound K . ' - . 
https://www.ncbi.nlm.nih.gov/pubmed/27606833

(2015), 14 ( 22-52) ' ( 1800 " -200 " ) (200 " ). . ' -DNA . -DNA -17% (p=0.0156) ' , . (p=0.0021).
https://www.ncbi.nlm.nih.gov/pubmed/26393910

 


- ( 2013) ' . 364 -40 " – 2000 " ' 8 . (p=0.003). ( 30% ) ' (30% 20%). , (p=0.01) (p=0.07). 
https://www.ncbi.nlm.nih.gov/pubmed/23853057

( 2010) ' . 290 (4 ) ' ( 5% Ginsenosides) 750, 1000 2000 " . 175 . (p=0.08) p=0.39)) (1000 - 2000 ") (750 "). ' (40% 17%). 
https://www.ncbi.nlm.nih.gov/pubmed/19415341
( 2017) ' (Methylphenidate) (Cancer related fatigue). 28 3 ( 10) (ESAS- Edmonton symptom assessment scale) / ' 2000 " ( ) ( 10-40 " ) 30.5 . 15 ( , , ). 60% , ( 2.8 p<0.0002).
https://www.ncbi.nlm.nih.gov/pubmed/28299946

 


(Cohort) (2006) 1455 ' (Panax ginseng - Panax quenqefoilum) (Survival) (Quality of life). -27% ' . ' (0.71) (0.70) . , ' , ' , , (p<0.01-0.04). (p=0.01). , -Tamoxifen ( ) ' ' (p=0.02).
https://www.ncbi.nlm.nih.gov/pubmed/16484447

 

 

 | 

 

(2006) (NSCLC) . 34 2815 . . ( ), , . , .
 https://www.ncbi.nlm.nih.gov/pubmed/16421421
(2003) . 60 (NSCLC – Non Small Cell Lung Cancer) . (Mitomycin C, Vinblastine, Cisplatin). 60 " . -120 . 2-3 21-28 . (40%) (36.7%) , , NSCLC . 
https://www.ncbi.nlm.nih.gov/pubmed/14626183
(2014) . 120 . , 250 " 20 " . 21 . ( ), (22).
(ALL – Acute Lymphoblastic Leukemia) . 105 -ALL 2009 2012. ( , ) , . , . ( 0.5-1 " " ). -1-2 . . -19 , . ( 79% ), * .
* .
https://www.ncbi.nlm.nih.gov/pubmed/24568906 

 

 

(2005) . , , , , . , . , (Tropisetron, Sulpiride ) .
342 . , ( ) . .
 https://www.ncbi.nlm.nih.gov/pubmed/15674951
(2012) (PG2) . 75 . PG2 500 ", , . PG2 ( : PhytoHealth Corp., Taiwan) . . , PG2. PG2 . -PG2 (57% 32% ) , . , 82% PG2 . -71% PG2 , . ( ) PG2 . ( , ).
https://www.ncbi.nlm.nih.gov/pubmed/22309959
(2012) . 136 NSCLC . (Vinorelbine -Cisplatin) . . . (QOL), , , , . , .
https://www.ncbi.nlm.nih.gov/pubmed/21928106
(2014) ST36 ( ) . 67 . , . ST36. . . , (BUN) . , .
 http://en.cnki.com.cn/Article_en/CJFDTotal-SHZJ201402024.htm
(2005) ST36 . 78 . 4 " ST36 ( -8 ), . (Leucogen, Lithium carbonate) (Gan Xue Bao). . -15 . ST36 . , NK 2. 
https://www.ncbi.nlm.nih.gov/pubmed/15889516
(2014) . 91 . (0.5 " ) 35 , . . . , .
https://www.ncbi.nlm.nih.gov/pubmed/24568907

 

 

(2017) . 37 50% 20 " . (p=0.04) (p=0.03) . , 2-3 (p<0.001).
https://www.ncbi.nlm.nih.gov/pubmed/29296112
(2017) triamcinolone acetonide . 60 ( 57.33) 2-3 ( 0-4) 0.5 " triamcinolone acetonide 0.18 " ( , ) . , . (VAS). (p<0.05) , (p<0.05 , ).
https://www.ncbi.nlm.nih.gov/pubmed/25347930
(2011) . 75 (85.3% , 30-60) : 1: 20 " . 2: . 3: , 4: . . . (p<0.001 1 , 2 ), . 
https://www.ncbi.nlm.nih.gov/pubmed/22408302

 

 

 

 

 ( 2017) ( ) . -, , .

6,235 , . -9.4 1,224 . ( 1.5 " ) -21% ( 0.3 " ). ( ).
: , . 
https://www.ncbi.nlm.nih.gov/pubmed/28263368

( 2015)   , ' (Panax ginseng), , ,   (Camellia sinensis), ' , (Allium sativum), , ''

http://www.ncbi.nlm.nih.gov/pubmed/26651248

( 2015) . .

.

, , , , EGCG ( ), , , , ''

http://www.ncbi.nlm.nih.gov/pubmed/26503998

( 2015) (in vitro) (in vivo) ' ( ).

' : , , , , , , , , . , ' , .

', ( ) ( ). 

http://www.naturopedia.com/article.asp?rId=880

http://www.ncbi.nlm.nih.gov/pubmed/26593532

, -.

, ( ), , , , , 2 , , . , , ( ).

, - .  
:  . : http://www.naturopedia.com/article.asp?rId=880

https://www.ncbi.nlm.nih.gov/pubmed/27723080

, ( 2017), ', , ( ) - , ' .

 https://www.ncbi.nlm.nih.gov/pubmed/28148690

 ( 2017) - . 365 , 2006-2012 (, , ) 1-5 . 
, , , , . 431 / -865 /, . ( 24 /) . , . , ( 70 /) . 
https://www.ncbi.nlm.nih.gov/pubmed/29230660

 

 

 

( 2015) - ( - HCC).

ALT -HCC.

, ALT .

, - HCC.

: Sho-saiko-to, Juzen-taiho-to, SNMC (Scutellaria baicalensis) ' '.

- HCC. 

http://www.ncbi.nlm.nih.gov/pubmed/26457019

, (2019) , (Scutellaria baicalensis) , () . 

https://www.ncbi.nlm.nih.gov/pubmed/31291609

(2016) -

http://advances.sciencemag.org/content/2/4/e1501780

 

 

 (2021) (Withania somnifera) . 

https://pubmed.ncbi.nlm.nih.gov/33949906/

 ( 2016) , . : (Withania somnifera), (Tribulus terrestris), (Asparagus racemosus), (Azadirachta indica), (Ocimum sanctum) '' (Zingiber officinale). 
https://www.ncbi.nlm.nih.gov/pubmed/27681646

( 2015) , - - . 

http://www.ncbi.nlm.nih.gov/pubmed/26718910

( 2013)   . 100 2 8 . 51 ( 36-70) -50.5 ( 32-71). 77% 2 -3. : Taxotere, Adriamycin -Cyclophosphamide 5-Fluorouracil, Epirubicin -Cyclophosphamide. (p<0.001 -Piper Fatigue Scale , -p<0.003 Schwartz Cancer Fatigue Scale) -7 18 EORTC QLQ-C30 ( p<0.001). .
https://www.ncbi.nlm.nih.gov/pubmed/23142798

( 2015) - (Withania somnifera) . 

http://www.ncbi.nlm.nih.gov/pubmed/26334881

 

 


 | 

 

 

-


( 2016) (®Legasil) (Silybin) (NSCLC-Non Small Cell Lung Cancer). Legasil® 210 " Eurosil 85(60% *) (Silybum marianum). 
62 . - dexamethasone ( ), (Carboplatin) Pemetrexed. 16 , MRI 20% . ®Legasil. . Pemetrexed (5 ). 4 79% . -®Legasil 6 84% .
67 . Pemetrexed. 4 MRI (" 15% ). ®Legasil 3 ( ). . (69% ).
, .
* Eurosil 85 - 80%.
https://www.ncbi.nlm.nih.gov/pubmed/26959886

 (2019) , , . 

https://www.ncbi.nlm.nih.gov/pubmed/31407422

 

-


( 2016) (Livergol®), (Silybum marianum), * . 27 . 420 " . , (World Health Organization and National Cancer Institute-Common Terminology-Criteria oral mucositis grading scale) ( : p<0.05). , . 
https://www.ncbi.nlm.nih.gov/pubmed/27555604
( 2010) (.Siliphos® Thorne Research, Inc) (Silibinin) 21 (ALL-Acute Limphoblastic Leukemia) . 50 - ALL . - Siliphos®, 80-320 " (5.1 " " ) 28 . Siliphos® (Silybum marianum) 33% 1:2 . ( ALT, AST, ). , 28 (56 ), - AST ( : p=0.05) - ALT ( : p=0.07). , ( ) 61% 72% .
https://www.ncbi.nlm.nih.gov/pubmed/20014183
( 2011) Leviaderm(®) (Silymarin) . 101 (0.25% ) Panthenol ( ). . , (45 29 , p<0.0001). 23.5% 2% . 3 2% 28% .
https://www.ncbi.nlm.nih.gov/pubmed/21786113

 

 

- , ( 2016), .

, .

, , .

-, ( ) . . ( ).

, .

, , .
: . .  .

http://www.ncbi.nlm.nih.gov/pubmed/27155666

 

 

 

-  (2018) . Xi huang (Calculus Bovis), / (She Xiang - ), (Boswellia) (Commiphora molmol). 15 815 (, , , , , ).

-35% -13% , -20% . , . , . 

https://www.ncbi.nlm.nih.gov/pubmed/30539838

( 2014) NSCLC .

69 , (Gemcitabine, Alimta docetaxel) (), - .

21 , , . 12.43 10 . . 

, .    

http://www.ncbi.nlm.nih.gov/pubmed/24941837

( 2015) ( ) .

33 - -.

12 6 . .

( 7.06 3.30). 2-3 .

.

http://www.ncbi.nlm.nih.gov/pubmed/25918996

, ( 2016), Kuan-Sin-Yin .

Kuan-Sin-Yin , : (Codonopsis pilosula), (Atractylodes macrocephala), (Glycyrrhiza uralensis), (Poria cocos), (Astragalus membranaceus), (Ligustrum lucidum) -Agastache rugose.
52 , - , - , . , . 
( ) (heart-rate variability) , .

, . , .
https://www.ncbi.nlm.nih.gov/pubmed/27912948

( 2015) -26,000 , . 

http://www.ncbi.nlm.nih.gov/pubmed/25934515

- ( 2016) NSCLC ( Nonsmall Cell Lung Cancer) , .

- 14 61 4,247 .

11 , 6 : Kang-lai-te injection, Shei-qi-fu-zheng injection,Shen-fu ingection, Zi-jin-long tablet, Compound Ku-shen injection ( ), Kang-ai- injection ( ). Hai-shen-su Tegillarca granosa. - .

http://www.ncbi.nlm.nih.gov/pubmed/26735544

- ( 2016) SH003 . SH003 :

Astragalus membranaceus ,Angelica gigas ,Trichosanthes kirilowii Maximowicz.

.

, , .

http://www.ncbi.nlm.nih.gov/pubmed/27476488

 ( 2016) ( 4)
154 , , -58 . 12 , 18 , 9 (p<0.001).

13 , 204 , , (Glycyrrhiza glabra), (Scutellaria barbata), (Scutellaria baicalensis), (Codonopsis pilosula), (Bupleurum spp), (Salvia miltiorrhiza) (Curcuma longa).

. .  
https://www.ncbi.nlm.nih.gov/pubmed/27583849

( 2018) , , Gambogic acid, , Tanshinon, , ', Tetramethylpyrazine, . 

https://www.ncbi.nlm.nih.gov/pubmed/29860581

( 2015) . (TJ-41, Liu-jun-zi-tang, PHY906, Coumarin, Aescine) , , , , , . (', , , TJ-48, Huachansu, Shenqi fuzheng, Kanglaite) .

, , , , .

, , , , . 

http://www.ncbi.nlm.nih.gov/pubmed/25787906

( 2015) -, ().

http://www.ncbi.nlm.nih.gov/pubmed/26056434

( 2015) SQDBT ( Shi Quan Da Bu Tang) .

12 : Panax ginseng, Atractylodes macrocephala, Wolfiporia extensa, Glycyrrhiza glabra, Rehmannia glutinosa prepatarta (Shu di huang), Paeonia lactiflora, Angelica sinensis, Ligusticum chuanxiong, Cinnamomum cassia, Astragalus membranaceus, Zingiber officinale, Ziziphus jujube.

. , . (placental growth factor) . 

http://www.ncbi.nlm.nih.gov/pubmed/25895458

Shenling Baizhu San (: SBS) . 10 : Panax ginseng, Atractylodes macrocephala, Wolfiporia extensa, Glycyrrhiza glabra, Dioscorea opposite, Dolichos lablab, Nelumbinis Nucifera, Coix lacryma-jobi, Amomum, Platycodon grandifloras.

( 2015), ,

http://www.ncbi.nlm.nih.gov/pubmed/25897964

( 2014) Chang-Wei-Qin - Oxaliplatin.

http://www.ncbi.nlm.nih.gov/pubmed/25103530

( 2015) PHY906-KD018  - Sorafenib

http://www.ncbi.nlm.nih.gov/pubmed/25819872

 ( 2016) Jianpi Ligan (unresectable hepatocellular carcinoma).

103 , (transarterial chemoembolization) 2007-2013. , 50 -53 . : (Codonopsis pilosula), (Atractylodes macrocephala), (Poria cocos), (Glycyrrhiza glabra) (Dioscorea villosa), (Pinelliae Ternatae), (Crataegus spp), (Nelumbinis), (Artemisia scoparia) -Pericarpium Arecae.

, , . , , . (51/53 40/50 ) 3 (38% 26%).
.
https://www.ncbi.nlm.nih.gov/pubmed/27536066

 

 

 

 (2019) , . 43 , 3,239 -13 , 31 . -21 , -22 - . " -32 , (18 ), (6 ) '' (5 ). 

- , , , , , , , , , , , , , , , , , , . ,

, .

https://pubmed.ncbi.nlm.nih.gov/31779991/

 (2019) . 43 (31 ), 1995-2019 3,239 -13 . -21 1 -6 2-20 . -22 2-50 " / 3-10 , , . , " -32 , (18 ), (6 ) '' (5 ). . 

, , , , , , , , , , , , , , , , . 

, .

https://www.sciencedirect.com/science/article/abs/pii/S0965229919308647

( 2014) .

280 . -3 : , , . 
5 3 , , , , , 2:2:2:1:1:1, 1.1% . 35 3 . 
6 -10 : , (p<0.001) , (p<0.05). , , .

, (-123.2 -112.5) , (-117.4 -123.0, -125.8 -136.0 -110.9 -146.0, ). (-60.8 -67.2) , (-65.5 -61.0 , -60.3 -54.8 -67.3 -47.3 ). 
.

http://www.ncbi.nlm.nih.gov/pubmed/25157942

- . , - . 40 , 20 . (90%), (86%), (81%), (67%) (52%).

, , 11 -8 . . - .

: . 

https://www.ncbi.nlm.nih.gov/pubmed/30377210

 (2020) , . 90 , . ( 3% ) , , . . 0 10. 

(Folfirinox, Paclitaxel-Trastuzumab, Carboplatin-Paclitaxel, Cyclophosphamide-Adriamycin), Cisplatin. (INRV (Index of Nausea, Vomiting, and Retching. 

, , .  

https://pubmed.ncbi.nlm.nih.gov/33197662/

( 2014) , , , .

24 ( RadiaPlexRx™) 3 , .

4 : (2.5%), (5%), (5%) (5%) (32.5%), (30%), (10%) (10%).

3 (, ) , . , . 
3, 6 -10 .

http://www.ncbi.nlm.nih.gov/pubmed/24668063

 

 

 |  3 |  D |   | 

 

 

- ( 2016) ( ) .  11 26,606 -873,000 7 .  (345-1750 " ) -8% (203-807 " ). ( 25% 6% ). 300 "/ 2% , 8% -2% , .   , .

http://www.ncbi.nlm.nih.gov/pubmed/27170091

 (2020) . , . 22 2 3, . Flavopiridol - 50 mg/m2. , :

  • - 140 88 " 615 -11 .
  • - 4 21 " 525 -12 .

, .  

https://pubmed.ncbi.nlm.nih.gov/31752046/

- (2021), . , , , , . , , .  14 . , , , , , . .  , .   

https://pubmed.ncbi.nlm.nih.gov/33891786/

 (2021) - Q10 , . - Q10 - ( ) , . - Q10 , . , - Q10- Q10 ; ; - , , , ; ; ; ; . , - Q10 ( ) 900 " . , , .  - Q10 200 "/ . , -, . , - Q10

https://pubmed.ncbi.nlm.nih.gov/34067632/

, , . , - - . ( 2015) - , , , , EGCG, , , '' . . . 

http://www.ncbi.nlm.nih.gov/pubmed/25693744

12 , 500 " 1 , 4 11 . 

https://www.ncbi.nlm.nih.gov/pubmed/17172008

( 2016) ( ), 22 , . E .   

http://www.ncbi.nlm.nih.gov/pubmed/27175595

 (2021) - C , .  C, - , C, C . C , , , , , . 

:

  • - , , . 

  • , - C . , , . 

.        

https://pubmed.ncbi.nlm.nih.gov/33652579/

( 2016) . fisetin, EGCG, , , , , , , , -3- .

http://www.ncbi.nlm.nih.gov/pubmed/26864554

(2016) - , . 3 , -EGCG Ziziphus jujube. , - ( ) ( ). . 

https://www.ncbi.nlm.nih.gov/pubmed/26156544

-  (2019) Clostridium butyricum . , Clostridium butyricum . 41 , . , 3 , 420 " - - 3 3 . . . , , . , , . , Clostridium -Lactobacillus . Clostridium butyricum .  (National Natural Science Foundation of China). 

https://www.ncbi.nlm.nih.gov/pubmed/30854059

,  ( 2017), , . 7 5 . , . 10 "/" , . , 1 "/" . – . -, , -. .

https://www.ncbi.nlm.nih.gov/pubmed/28282956

( 2015)  

http://www.ncbi.nlm.nih.gov/pubmed/26541610

( 2015) -

http://www.ncbi.nlm.nih.gov/pubmed/25705818

( 2015) -

http://www.ncbi.nlm.nih.gov/pubmed/25976785

( 2015) , , , " ( ). 

http://www.ncbi.nlm.nih.gov/pubmed/25695860

 ( 2017) C . , C , . 

https://www.ncbi.nlm.nih.gov/pubmed/28223550

- ( 2016), , . 685 70 , 45% . : , , , - - . . , 87% (598 ) . , 89% (272) 36% (135) . 
, , -, . .
https://www.ncbi.nlm.nih.gov/pubmed/27243607

- ( 2017) E . 11 , " 435,532 – 4,164 . , E -16% - . -5% 2 "/ E. , . E , -. E , -, E -. 

https://www.ncbi.nlm.nih.gov/pubmed/28244705

 (2017), (AICR) (WCRF), . , 2007, 99 ( ) - -29 -250,000 . , ( ), , (-500 '/), , , , , . , , - C, , D -, ( -100 ) ( ) .  - , , , , , , , 3 , , , , , , , , , , A, B6, E, , , -, , , . 
-47% , . 
http://www.aicr.org/continuous-update-project/colorectal-cancer.html

 ( 2016) - - (, ).  - , , , C , , (Bowman-Birk inhibitor) . ( ), , C . - .

https://www.ncbi.nlm.nih.gov/pubmed/26863913

 ( 2017) B3 , DNA, .

https://www.ncbi.nlm.nih.gov/pubmed/28681504

 ( 2017), (VITAL), B . 77,118 50-76, 808 . - 10 . B ( , B6 -B12) . , B6 -B12 ( -) 30-40% . , , B6 ( 20 "/) B12 ( 55 "/) . . , . 
https://www.ncbi.nlm.nih.gov/pubmed/28829668

 ( 2017) . -15 , 8 14 Bifidobacterium lactis -7 Lactobacillus acidophilus. , , 21 . , Fusobacterium, Selenomonas - Peptostreptococcus . , Faecalibacterium -Clostridiales Fusobacterium -Peptostreptococcus. ,

https://www.ncbi.nlm.nih.gov/pubmed/28944067

 ( 2017) , . - , , , , . , , , . C , E . , , , . , . 

https://www.ncbi.nlm.nih.gov/pubmed/29049045

 ( 2017) , . 120 , -3 : , Bifidobacterium -lactobacillus. .  (5%) (30%) (60%). , . . , , - .

https://www.ncbi.nlm.nih.gov/pubmed/29069041

- ( 2017) ( - ). 5 2,234 . 720-2,000 "/ , , 3 5 . -12% , . - 1,600 "/ -26% -16% 1,200 "/. , . , .  : 500 " , , . 
https://www.ncbi.nlm.nih.gov/pubmed/28796047

-, (2019) , , 229 , 229 . :

https://www.ncbi.nlm.nih.gov/pubmed/30713028

 

3

- (2021), 3 , . 123 , 3 COPD, . 66 -, 3 , .  , 3 , (1).

https://pubmed.ncbi.nlm.nih.gov/34857251/

-  (2021) 3 . , 3 - , -70% . , , . 18 3 600 . 31 -. 28 -25 , 3 0.6 -3.96 /, -EPA / -12 -16 . , . - 26 3 , . , 3 -80% . .

https://pubmed.ncbi.nlm.nih.gov/34130028/

(2022), 3 , . , 3 , . 192 . 3 , 3 . , 3 . 3

https://pubmed.ncbi.nlm.nih.gov/35112608/

- (2022) 3 6 . - 3 , 3 3 6 . , -59% 3 . 3 . 6, 6 .  3 , 6. 

https://pubmed.ncbi.nlm.nih.gov/35096921/

(2021) 3 . .  . 85 , 4-36 . 6 , 6 3 . , 69% -31% .  3 , 6 3 . 3 , 6 .  3 0.36 "/" 3 , 0.21 "/" . , . , , 3 3 -NIH .
https://pubmed.ncbi.nlm.nih.gov/35011059/

- (2021) 3 . , 3, 3 .  16 64 , 3,680 "/ 3 , .  , 3 . 3 , 3 3 , (2). 

https://pubmed.ncbi.nlm.nih.gov/34857226/

2010 " - , 3 D , .  , 25,871 : 13,085 55 -12,786 50, ", .  -4 :

  • D 2,000 "/ + (®Omacor) 1 / (465 " EPA -375 " DHA)

  • D + .

  • + . 

  • + .

2011 2014, 2017, 5.3 .  2018, (AHA) New England Journal of Medicine. , , , , , , .  (1):

 D (2)

  • : D, (793 824 , ), , . , D , -25% . 

  • : D, (396 409 , ) , , . 

  • : D , ,

, D D

3 (3)

  • : 8%, , (386 419 , ). , . , -28%, -50%, . 3 22% ( ). 

  • : , (820 797 , ), , , , . 

  • : , . 

  • -: , ( 1.5 ), 19% 40% , ( 1.5 ).  

  • , , -, . 

, D , . 3 , , . 

 

 :

  • (AHA), 2020, (VITAL-Rhythm) D 3 (AF). , D 3 , 3 . , , (4).   

  • , D , -BMI. 1,617 , D, -17% ( 1.7% 2.1%). BMI , BMI 25 ( -38% -11% BMI 25-30 -5% BMI 30)(5). 

  1. http://www.vitalstudy.org/findings.html
  2. https://pubmed.ncbi.nlm.nih.gov/30415629/
  3. https://pubmed.ncbi.nlm.nih.gov/30415637/
  4. https://professional.heart.org/es/meetings/scientific-sessions
  5. https://pubmed.ncbi.nlm.nih.gov/33206192/

 ( 2017) 3 .

61 , - (-'), , -5- . 3 (900 " - ) (250 " - ) 15 (3 -12 ). . , 3 , 3 () (p=0.018), , , (16.1% 36.7%, p=0.068) ( AST -ALT, p=0.012 -p=0.015, ). 3

https://www.ncbi.nlm.nih.gov/pubmed/27644137

- ( 2017) 3 , . - -, , - 3 . , 623 , . 3 ( ), , , CRP - IL-6 T CD3 -CD4. , TNF-α 3  T CD8 . 3 5-7 . : , 3 , . , . 

https://www.ncbi.nlm.nih.gov/pubmed/28410575

( 2016), 3 1,659 . 3 , 0.3 3 -40% , 0.1 3. , 3 0.15 -70% 3. 3 . 3 .  

http://www.ncbi.nlm.nih.gov/pubmed/27436272

(2016) - , . 3 , -EGCG Ziziphus jujube. , - ( ) ( ). . 

https://www.ncbi.nlm.nih.gov/pubmed/26156544

 ( 2017), , 3 (CYP4F11) 6 (CYP4A11). 6 3. 3 3 , . , 6 . . 
https://www.ncbi.nlm.nih.gov/pubmed/28557975

- (2018) 3, -, . , 457 - , . 3 6 1:4 1:3 ( 6) 0.2 /" 3, 6 , 5-7 . 3 -64% -2.3 . 3 . 3 , .
https://www.ncbi.nlm.nih.gov/pubmed/29222889

-  ( 2017), , 3 ( ), . 60 , 3 ( 360 " EPA -240 " DHA) , 3 . 3, 3 100% 3 33% . 4 -9 3, 10 . 3 , , .  
https://www.ncbi.nlm.nih.gov/pubmed/29324423

,  ( 2017), 3 3
https://www.ncbi.nlm.nih.gov/pubmed/29413488

 ( 2018) 3 ( ) . 27 , 3 (Racol®) . , (LipaCreon®) . , 4 -8 . 4 -8 . 3 . : .

https://www.ncbi.nlm.nih.gov/pubmed/29599363

 

D

- D -  (2022) D . D , D. 12 72,669 . D . 2 -5.3 .  :

  • -6 61,882 . D . , D ( ) -16% . , D -37% .
  • -11 51,369 . D (, , , ).

D , .

-  (2022) D . 13 (12 ), (6 ) (10 ). -8 D 400 4,000 " -5 20,000 " -500,000 " . 3 -10 .

:

  • D , ( ). , -24% .
  • D . , D -13% .
  • D -5% . -7%, .

, , D , .

https://pubmed.ncbi.nlm.nih.gov/35954381/

https://pubmed.ncbi.nlm.nih.gov/35676320/

-  (2022) D . D , D . -11 , 6 -5 . (9 ), (8 ), (3 ) (3 ). D , D -13% . . , - . D , .

https://pubmed.ncbi.nlm.nih.gov/36014928/

-  (2019) D . 52 , 75,454 , D . " 8,033 , 1,331 -877 . D . , D -16% . - D , D3 D2. 

https://pubmed.ncbi.nlm.nih.gov/31405892/

-  (2019) D . - , ( 1,100 "/). , .  : , 3-10 6,537 . D 54-135 /, . , D : , 3-10 1,591 . D -13% . , ().  D , .

https://www.ncbi.nlm.nih.gov/pubmed/30796437

2010 " - , 3 D , .  , 25,871 : 13,085 55 -12,786 50, ", .  -4 :

  • D 2,000 "/ + (®Omacor) 1 / (465 " EPA -375 " DHA)

  • D + .

  • + . 

  • + .

2011 2014, 2017, 5.3 .  2018, (AHA) New England Journal of Medicine. , , , , , , .  (1):

 D (2)

  • : D, (793 824 , ), , . , D , -25% . 

  • : D, (396 409 , ) , , . 

  • : D , ,

, D D

3 (3)

  • : 8%, , (386 419 , ). , . , -28%, -50%, . 3 22% ( ). 

  • : , (820 797 , ), , , , . 

  • : , . 

  • -: , ( 1.5 ), 19% 40% , ( 1.5 ).  

  • , , -, . 

, D , . 3 , , . 

 :

  • (AHA), 2020, (VITAL-Rhythm) D 3 (AF). , D 3 , 3 . , , (4).   

  • , D , -BMI. 1,617 , D, -17% ( 1.7% 2.1%). BMI , BMI 25 ( -38% -11% BMI 25-30 -5% BMI 30)(5). 

  1. http://www.vitalstudy.org/findings.html
  2. https://pubmed.ncbi.nlm.nih.gov/30415629/
  3. https://pubmed.ncbi.nlm.nih.gov/30415637/
  4. https://professional.heart.org/es/meetings/scientific-sessions
  5. https://pubmed.ncbi.nlm.nih.gov/33206192/

- (2022) D , . D 4,000 "/ 12 D. D , D.  150 D , . D

https://pubmed.ncbi.nlm.nih.gov/35159013/

- , (2019) , D 1 3. 417 66 - 10% , 42% -48% . D 2,000 "/ - 3.5 . (20% -26% ) 5 (82% -81% ). , D ( 20 40 /") 5 85% 71% . , D

https://www.ncbi.nlm.nih.gov/pubmed/30964526

- , (2018) D . 5,110 50-84, D ( ) 200,000 " 100,000 ", . 2.5-4.2 ( 3.3 ). 328 , 6.5% D -6.4% . D , D .

https://www.ncbi.nlm.nih.gov/pubmed/30027269

 (2021) D , . , D , D .  500 , 136 D . D .  66.8% D ( -30 /"), 31.6% D. D , , (SCC), -BMI.  , D 2,250 "/, . . 

https://pubmed.ncbi.nlm.nih.gov/34130032/

( 2016) 190 , D

http://www.ncbi.nlm.nih.gov/pubmed/26903577

( 2016) D . D , 1 2 . D 1. 2, D , . D 1 -2, D . , D

http://www.ncbi.nlm.nih.gov/pubmed/27030935

( 2016) D . D . 1,169 55 D 30 /" . 1,135 55 D 48 /" . ( ) D -4 . D , D -40 /" -67% D -20 /". D D ( , ). 

http://www.ncbi.nlm.nih.gov/pubmed/27049526

 (2021) , D 50. - D.  , 50 - (-13%). -40,000 , D -25 .  , D 50 -30,000 , -900 1.154 , 254 .  D

https://pubmed.ncbi.nlm.nih.gov/33540476/

 (2017), (AICR) (WCRF), . , 2007, 99 ( ) - -29 -250,000 . , ( ), , (-500 '/), , , , , . , , - C, , D -, ( -100 ) ( ) .  - , , , , , , , 3 , , , , , , , , , , A, B6, E, , , -, , , .  -47% , . 

http://www.aicr.org/continuous-update-project/colorectal-cancer.html

( 2018), , D . - 3,301 4,044 . (), D, , . D . , ( D, 36 / ), -19%, -25% -22% (49 / ), (58 / ) (75 / ), . . D

https://www.ncbi.nlm.nih.gov/pubmed/29514781

-  ( 2018) D - . 2,259 45-75 -11 ", . : 1,200 "/, D 1,000 "/, . 3-5 ( ), 3-5 ( ).  , 27% , 24% / (SSA/Ps) 5% . .  , 30% , 24% -SSA/Ps 6% . - SSA/Ps ( 2.65) D ( 3.81). D -SSA/Ps, 6-10 . 

https://www.ncbi.nlm.nih.gov/pubmed/29496722

- ,( 2018) -20 , D , D . 5,313 , 5,313 . . D , , , .

https://www.ncbi.nlm.nih.gov/pubmed/29617726

-17  ( 2018) D . 5,706 , , 7,107 . D 50-62.5 /, , D ( -30 /) -31% 75-87.5 87.5-100 / -19% -27%, . -100 /. -BMI, . -19% -7% 25 / D . D , . 75-100 /, -(IOM (Institute of Medicine. 

https://www.ncbi.nlm.nih.gov/pubmed/29912394

 

- ( 2014) – , . 9 -40% . 16 . 8 -34% . .

http://www.ncbi.nlm.nih.gov/pubmed/24224911

( 2016)   .  , , . , , , , , , , ( , , , , ) , . . (NTD). , -

http://www.ncbi.nlm.nih.gov/pubmed/27008500

 ( 2017) . - -DNA, -DNA. , . . , , . , , .  400 " , 600 " -500 " . , , .

https://www.ncbi.nlm.nih.gov/pubmed/28588742

 ( 2017), (VITAL), B . 77,118 50-76, 808 . - 10 .  B ( , B6 -B12) . , B6 -B12 ( -) 30-40% . , , B6 ( 20 "/) B12 ( 55 "/) . . , . 

https://www.ncbi.nlm.nih.gov/pubmed/28829668

 

 

 (2021) . , , , (, , ), ( , ), , . . , , , . , , , , , . (DRI). , 40 "/, -11 "/ , . 100-200 "/ . 900 "/ , , , . 
, , , , , U . , .

https://pubmed.ncbi.nlm.nih.gov/34065478/

- ( 2016) ,

http://www.ncbi.nlm.nih.gov/pubmed/27357089

-, (2019) , , 229 , 229 . :

https://www.ncbi.nlm.nih.gov/pubmed/30713028

 ( 2016) - - . , -, , .

32 50 (Se≤1.36 µmol/l), -3 6 :

  1. (-48 "/). 
  2. (800 "/ EGCG).
  3. + .

/ , - (SePP), (β-catenin), (NF-κB) (DNMT1). .
https://www.ncbi.nlm.nih.gov/pubmed/27923410

 ( 2017) , . - , , , , . , , , .

C , E . , , , . , . 
https://www.ncbi.nlm.nih.gov/pubmed/29049045

 

 

:

  1. Dawit Kidane et al. Interplay between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol. Jan 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300235/
  2. Alberto Mantovani et al. Review Article Cancer-related inflammation. Nature. Jul 24, 2008. http://www.nature.com/nature/journal/v454/n7203/full/nature07205.html 
  3. Aaron J. Schetter, Niels H. H. Heegaard, Curtis C. Harris. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. Jan 2010. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802675/
  4. Shiels MS et al. Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst. Dec 2013. http://www.ncbi.nlm.nih.gov/pubmed/24249745
  5. Sharon R. Pine et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst.  Jul 2011. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139587/
  6. Fernandez-Garcia B et al. Prognostic significance of inflammatory factors expression by stroma from breast carcinomas. Carcinogenesis. May 19, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27207649
  7. Eiró N et al. Analysis of the expression of interleukins, interferon β, and nuclear factor-κ B in prostate cancer and their relationship with biochemical recurrence. J Immunother. Sep 2014 . http://www.ncbi.nlm.nih.gov/pubmed/25075566
  8. Koshiol J et al. Association of inflammatory and other immune markers with gallbladder cancer: Results from two independent case-control studies. Cytokine.  Jul 2016. http://www.ncbi.nlm.nih.gov/pubmed/27173614
  9. Ismar Rasic, Svjetlana Radovic, Goran Aksamija. Relationship Between Chronic Inflammation and the Stage and Histopathological Size of Colorectal Carcinoma. Med Arch. Apr 2016 . http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851510/
  10. Zamora-Ros R et al. Dietary inflammatory index and inflammatory gene interactions in relation to colorectal cancer risk in the Bellvitge colorectal cancer case-control study. Genes Nutr. Jan 2015. http://www.ncbi.nlm.nih.gov/pubmed/25488145
  11. Kiyabu GY et al. Fish, n - 3 polyunsaturated fatty acids and n - 6 polyunsaturated fatty acids intake and breast cancer risk: The Japan Public Health Center-based prospective study. Int J Cancer. Dec 15, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26147326
  12. Lisa C Vinikoor et al. trans-Fatty Acid Consumption and its Association with Distal Colorectal Cancer in the North Carolina Colon Cancer Study II. Cancer Causes Control. Oct 20, 2009. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809818/
  13. Zamora-Ros R et al. Dietary inflammatory index and inflammatory gene interactions in relation to colorectal cancer risk in the Bellvitge colorectal cancer case-control study. Genes Nutr. Jan 2015 . http://www.ncbi.nlm.nih.gov/pubmed/25488145
  14. Galas A, Kulig P, Kulig J. Dietary inflammatory index as a potential determinant of a length of hospitalization among surgical patients treated for colorectal cancer. Eur J Clin Nutr. Oct 2014. http://www.ncbi.nlm.nih.gov/pubmed/25005677
  15. Nagendra Sastry Yarla et al. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Semin Cancer Biol. Feb 4, 2016. http://www.ncbi.nlm.nih.gov/pubmed/26853158
  16. Turner-McGrievy GM et al. Randomization to plant-based dietary approaches leads to larger short-term improvements in Dietary Inflammatory Index scores and macronutrient intake compared with diets that contain meat. Nutr Res. Feb 2015. http://www.ncbi.nlm.nih.gov/pubmed/25532675
  17. Medina-Remón A et al. Polyphenol intake from a Mediterranean diet decreases inflammatory biomarkers related to atherosclerosis: a substudy of the PREDIMED trial. Br J Clin Pharmacol. Apr 21, 2016. http://onlinelibrary.wiley.com/doi/10.1111/bcp.12986/full
  18. Salas-Salvadó J et al. Components of the Mediterranean-type food pattern and serum inflammatory markers among patients at high risk for cardiovascular disease. Eur J Clin Nutr. May 2008 . http://www.ncbi.nlm.nih.gov/pubmed/17440519?dopt=Abstract
  19. Erica M. Holt et al. Fruit and vegetable consumption and its relation to markers of inflammation and oxidative stress in adolescents. J Am Diet Assoc. Mar 2009. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676354/
  20. Akiko Nanri et al. Dietary patterns and C-reactive protein in Japanese men and women1,2,3. Am J Clin Nutr. May 2008 . http://ajcn.nutrition.org/content/87/5/1488.long
  21. Sciacca L et al. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis. Sep 2013. http://www.ncbi.nlm.nih.gov/pubmed/23932729
  22. Peter T. Campbell et al. Diabetes and Cause-Specific Mortality in a Prospective Cohort of One Million U.S. Adults. Diabetes Care. Sep 2012. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425000/
  23. Nour Makarem et al. Cancer Link Offers Another Reason to Avoid Highly Processed Carbs. Experimental Biology . Apr 2016. http://www.newswise.com/articles/cancer-link-offers-another-reason-to-avoid-highly-processed-carbs
  24. Craig J. Currie et al. Mortality After Incident Cancer in People With and Without Type 2 Diabetes. Impact of metformin on survival. Diabetes Care. Feb 2012. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263862/
  25. Trinidad P. Trinidad. Nutritional and health benefits of coconut sap sugar/syrup. FNRI Department of Science and Technology. http://www.pca.da.gov.ph/coconutrde/images/sugarpdfs/TPTrinidad_FNRI.pdf
  26. Harasym J, Oledzki R. Effect of fruit and vegetable antioxidants on total antioxidant capacity of blood plasma. Nutrition. May 2014. http://www.ncbi.nlm.nih.gov/pubmed/24698344
  27. Zhang M et al. Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women. Int J Cancer. Oct 1, 2008. http://onlinelibrary.wiley.com/doi/10.1002/ijc.24047/full
  28. Balazs Bodai, MD, Phillip Tuso, MD. Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations. Perm J. 2015. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403581/
  29. Brouwer CA et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. . Ann Oncol . 2006. http://www.ncbi.nlm.nih.gov/pubmed/16857723
  30. Kojima R, Toyama Y, Ohnishi ST. Protective effects of an aged garlic extract on doxorubicin-induced cardiotoxicity in the mouse. Nutr Cancer. 1994. http://www.ncbi.nlm.nih.gov/pubmed/14502845
  31. Dwivedi C et al. Effects of oil-soluble organosulfur compounds from garlic on doxorubicin-induced lipid peroxidation. Anticancer Drugs . 1998. http://www.ncbi.nlm.nih.gov/pubmed/9625441
  32. Thabrew MI et al. Protection by garlic against Adriamycin-induced alterations in the oxido-reductive status of mouse red blood cells. Phytother Res. May 2000. http://www.ncbi.nlm.nih.gov/pubmed/10815020
  33. Mukherjee S et al. Protection against acute Adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-α expression. BMC Pharmacol . Dec 2003. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC324401/
  34. Lang A et al. Allicin inhibits spontaneous and TNF-α induced secretion of proinflammatory cytokines and chemokines from intestinal epithelial cells. . Clin Nutr. Oct 2004. http://www.ncbi.nlm.nih.gov/pubmed/15380914
  35. Horie T et al. Protective effect of aged garlic extract on the small intestinal damage of rats induced by methotrexate administration. Planta Med . Aug 1999. https://www.thieme-connect.com/DOI/DOI?10.1055/s-1999-14023
  36. Alleviation by garlic of antitumor drug-induced damage to the intestine. J Nutr. Mar 2001. http://jn.nutrition.org/cgi/pmidlookup?view=long&pmid=11238819
  37. Khosla P, Karan RS, Bhargava VK. Effect of garlic oil on ethanol induced gastric ulcers in rats. hytother Res. Jan 2004. http://www.ncbi.nlm.nih.gov/pubmed/14750208
  38. Shu XO et al. Soy food intake and breast cancer survival. JAMA. Dec 9, 2009 . http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874068/
  39. Magee PJ, Rowland I. Soy products in the management of breast cancer. Curr Opin Clin Nutr Metab Care.  Nov 2012 . http://www.ncbi.nlm.nih.gov/pubmed/23075937
  40. Fritz H et al. Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS One.  Nov 28, 2013 . http://www.ncbi.nlm.nih.gov/pubmed/24312387
  41. Liu B et al. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res. Feb 1, 2005 . http://cancerres.aacrjournals.org/content/65/3/879.long
  42. van Duursen MB et al. Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model. Toxicol Appl Pharmacol. Jun 1, 2013 . http://www.ncbi.nlm.nih.gov/pubmed/23541764
  43. Ju YH et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res.  May 1, 2002 . http://cancerres.aacrjournals.org/content/62/9/2474.long
  44. González-Vallinas M et al. Modulation of estrogen and epidermal growth factor receptors by rosemary extract in breast cancer cells. Electrophoresis. Jun 2014. http://www.ncbi.nlm.nih.gov/pubmed/24615943?dopt=Abstract
  45. Tai J et al. Antiproliferation effect of Rosemary (Rosmarinus officinalis) on human ovarian cancer cells in vitro. Phytomedicine. Mar 2012. http://www.ncbi.nlm.nih.gov/pubmed/22325591?dopt=Abstract
  46. González-Vallinas M et al. Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells. Pharmacol Res.  Jun 2013. http://www.ncbi.nlm.nih.gov/pubmed/23557932?dopt=Abstract
  47. El-Naggar SA et al. Efficacy of Rosmarinus officinalis leaves extract against cyclophosphamide-induced hepatotoxicity. Pharm Biol.  Feb 1, 2016. http://www.ncbi.nlm.nih.gov/pubmed/26828825
  48. Ramachandran C et al. Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines. J Complement Integr Med. Aug 2012. http://www.ncbi.nlm.nih.gov/pubmed/22944718
  49. Ping Chen et al. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway. Tumor Biology. May 2015. http://link.springer.com/article/10.1007/s13277-014-2996-4
  50. Patel BB et al. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res. Feb 2010. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836443/
  51. Chen J et al. Curcumin and its promise as an anticancer drug: An analysis of its anticancer and antifungal effects in cancer and associated complications from invasive fungal infections. Eur J Pharmacol.  Feb 5, 2016 . http://www.ncbi.nlm.nih.gov/pubmed/26723514
  52. Rao S et al. The Indian Spice Turmeric Delays and Mitigates Radiation-Induced Oral Mucositis in Patients Undergoing Treatment for Head and Neck Cancer: An Investigational Study. Integr Cancer Ther. Oct 28, 2013 . http://www.ncbi.nlm.nih.gov/pubmed/24165896
  53. Hoa H. Le et al. Bisphenol A is released from polycarbonate drinking bottles and mimics the neurotoxic actions of estrogen in developing cerebellar neurons. Toxicol Lett. Jan 30, 2008. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2254523/
  54. Rafat A. Siddiqui. Omega 3-Fatty Acids: Health Benefits and Cellular Mechanisms of Action. Medicinal Chemistry. 2016. http://www.eurekaselect.com/80201/article?trendmd-shared=0
  55. Donatella D'Eliseo, Francesca Velotti. Omega-3 Fatty Acids and Cancer Cell Cytotoxicity: Implications for Multi-Targeted Cancer Therapy. J clin Med. Feb 2016. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773771/
  56. Ruth E. Patterson. Marine Fatty Acid Intake Is Associated with Breast Cancer Prognosis. J Nutr. Feb 2011. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021439/
  57. Kim J et al. Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk: a case-control study. BMC Cancer. Jun 30, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19566923
  58. Chan JM et al. Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control. Mar 2006. http://www.ncbi.nlm.nih.gov/pubmed/16425098
  59. Georgia Lenihan-Geels et al. Cancer Risk and Eicosanoid Production: Interaction between the Protective Effect of Long Chain Omega-3 Polyunsaturated Fatty Acid Intake and Genotype. J Clin Med. Feb 2016. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773781/
  60. Lovegrove C et al. Systematic review of prostate cancer risk and association with consumption of fish and fish-oils: analysis of 495,321 participants. Int J Clin Pract. Jan 2015. http://www.ncbi.nlm.nih.gov/pubmed/25495842
  61. Martinchik AN, Zubtsov VV. Phytoestrogenis properties of flaxseed lignans. Vopr Pitan. 2012. http://www.ncbi.nlm.nih.gov/pubmed/23530438
  62. Martinchik AN et al. Nutritional value and functional properties of flaxseed. Vopr Pitan. 2012. http://www.ncbi.nlm.nih.gov/pubmed/22888664
  63. Ulrika W. Nilsson Åberg et al. Tamoxifen and Flaxseed Alter Angiogenesis Regulators in Normal Human Breast Tissue In Vivo. PLoS ONE. Sep 30, 2011. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0025720
  64. Richard Béliveau, Denis Gingras. Role of nutrition in preventing cancer. Can Fam Physician. Nov 2007. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2231485/
  65. Norlaily Mohd Ali et al. The Promising Future of Chia, Salvia hispanica L. J Biomed Biotechnol. Nov 21, 2012. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518271/#B49
  66. Martínez-Cruz O, Paredes-López O. Phytochemical profile and nutraceutical potential of chia seeds (Salvia hispanica L.) by ultra high performance liquid chromatography. J Chromatogr A. Jun 13, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24811150
  67. Valdivia-López MÁ, Tecante A. Chia (Salvia hispanica): A Review of Native Mexican Seed and its Nutritional and Functional Properties. Adv Food Nutr Res. 2015. http://www.ncbi.nlm.nih.gov/pubmed/26319904
  68. V Vuksan et al. Reduction in postprandial glucose excursion and prolongation of satiety: possible explanation of the long-term effects of whole grain Salba (Salvia Hispanica L.). European Journal of Clinical Nutrition . Jan 2010. http://www.nature.com/ejcn/journal/v64/n4/full/ejcn2009159a.html
  69. Marineli Rda S et al. Chia (Salvia hispanica L.) enhances HSP, PGC-1α expressions and improves glucose tolerance in diet-induced obese rats. Nutrition. May 2015 . http://www.ncbi.nlm.nih.gov/pubmed/25837222
  70. Gonzales JF et al. Applying the precautionary principle to nutrition and cancer. J Am Coll Nutr. May 2014. http://www.ncbi.nlm.nih.gov/pubmed/24870117
  71. Federica Turati et al. Fruit and vegetables and cancer risk: a review of southern European studies. British Journal of Nutrition. Apr 2015. http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=9810951&fileId=S0007114515000148
  72. Park SY et al. Fruit and vegetable intakes are associated with lower risk of bladder cancer among women in the Multiethnic Cohort Study. J Nutr. Aug 2013. http://www.ncbi.nlm.nih.gov/pubmed/23739308
  73. Fang X et al. Landscape of dietary factors associated with risk of gastric cancer: A systematic review and dose-response meta-analysis of prospective cohort studies. Eur J Cancer. Dec 2015. http://www.ncbi.nlm.nih.gov/pubmed/26589974
  74. Aune D. et al. Fruits, vegetables and the risk of cancer: a multisite case-control study in Uruguay. Asian Pac J Cancer Prev. Jul-Sep 2009. http://www.ncbi.nlm.nih.gov/pubmed/19640185
  75. Bradbury KE et al. Fruit, vegetable, and fiber intake in relation to cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr. Jul 2014. http://www.ncbi.nlm.nih.gov/pubmed/24920034
  76. Carrie A. Thompson et al. Antioxidant Intake from Fruits, Vegetables and Other Sources and Risk of Non-Hodgkin Lymphoma: The Iowa Women's Health Study. Int J Cancer. Feb 15, 2010. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798902/
  77. Moyle CW et al. Potent inhibition of VEGFR-2 activation by tight binding of green tea epigallocatechin gallate and apple procyanidins to VEGF: relevance to angiogenesis. Mol Nutr Food Res. Mar 2015 . http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681316/
  78. Singh SV et al. Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res. Mar 1, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19223537
  79. Lenzi M et al. Sulforaphane as a promising molecule for fighting cancer. Cancer Treat Res. 2014. http://www.ncbi.nlm.nih.gov/pubmed/24114482
  80. Tomczyk J, Olejnik A. Sulforaphane--a possible agent in prevention and therapy of cancer. Postepy Hig Med Dosw. Nov 29, 2010. http://www.ncbi.nlm.nih.gov/pubmed/21160094
  81. Abdull Razis AF, Noor NM. Cruciferous vegetables: dietary phytochemicals for cancer prevention. Asian Pac J Cancer Prev. 2013. http://www.ncbi.nlm.nih.gov/pubmed/23679237
  82. Tse G, Eslick GD. Cruciferous vegetables and risk of colorectal neoplasms: a systematic review and meta-analysis. Nutr Cancer. 2014. http://www.ncbi.nlm.nih.gov/pubmed/24341734
  83. W Watson G et al. Phytochemicals from cruciferous vegetables, epigenetics, and prostate cancer prevention. AAPS J. Oct 2013. http://www.ncbi.nlm.nih.gov/pubmed/23800833
  84. Lam TK et al. Cruciferous vegetable consumption and lung cancer risk: a systematic review. Cancer Epidemiol Biomarkers Prev.  Jan 2009. http://www.ncbi.nlm.nih.gov./pubmed/19124497
  85. Tang L et al. Cruciferous vegetable intake is inversely associated with lung cancer risk among smokers: a case-control study. BMC Cancer. Apr 27, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20423504
  86. Holly L. Nicastro et al. Garlic and onions: Their cancer prevention properties. Cancer Prev Res (Phila). Jan 2015. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366009/
  87. Xiao D et al. Diallyl trisulfide inhibits angiogenic features of human umbilical vein endothelial cells by causing Akt inactivation and down-regulation of VEGF and VEGF-R2. Nutr Cancer. 2006. http://www.ncbi.nlm.nih.gov/pubmed/16965246
  88. Hantz HL, Young LF, Martin KR. Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp Biol Med (Maywood). Mar 2005. http://www.ncbi.nlm.nih.gov/pubmed/15734720
  89. Ke Zu, Lorelei Mucci, Bernard A. Rosner et al. Dietary Lycopene, Angiogenesis, and Prostate Cancer: A Prospective Study in the Prostate-Specific Antigen Era. J Natl Cancer Inst. Feb 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952200/
  90. Ilic D, Forbes KM, Hassed C. Lycopene for the prevention of prostate cancer. Cochrane Database Syst Rev. Nov 9, 2011 . http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008007.pub2/full
  91. Haseen F et al. Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review. Prostate Cancer Prostatic Dis. 2009. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0027481/
  92. Friedman, Mendel. Chemistry and Anticarcinogenic Mechanisms of Glycoalkaloids Produced by Eggplants, Potatoes, and Tomatoes. J. Agric. Food Chem. Mar 30, 2015. http://pubs.acs.org/doi/abs/10.1021/acs.jafc.5b00818
  93. Zhang F et al. Anticancer function of α-solanine in lung adenocarcinoma cells by inducing microRNA-138 expression. Tumour Biol. Dec 2, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26631041
  94. Shen KH et al. α-Solanine inhibits invasion of human prostate cancer cell by suppressing epithelial-mesenchymal transition and MMPs expression. Molecules. Aug 11, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25116803
  95. Hongwei Sun et al. Solanine Induces Mitochondria-Mediated Apoptosis in Human Pancreatic Cancer Cells. Biomed Res Int. May 11, 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037623/
  96. Chongqing Lv et al. Antitumor Efficacy of α-Solanine against Pancreatic Cancer In Vitro and In Vivo. PLoS One. Feb 5, 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914882/
  97. Deendayal Patel, Sanjeev Shukla, Sanjay Gupta. Apigenin and cancer chemoprevention: Progress, potential and promise (Review). International Journal of Oncology. Jan 1, 2007. http://www.spandidos-publications.com/ijo/30/1/233
  98. Esther Lai-Har Tang et al. Petroselinum crispum has antioxidant properties, protects against DNA damage and inhibits proliferation and migration of cancer cells. Journal of the Science of Food and Agriculture. Feb 19, 2015. http://onlinelibrary.wiley.com/doi/10.1002/jsfa.7078/full
  99. Lefort ÉC, Blay J. Apigenin and its impact on gastrointestinal cancers. Mol Nutr Food Res. Jan 2013. http://www.ncbi.nlm.nih.gov/pubmed/23197449
  100. Zhu Y, Wu J, Li S et al. Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer. Mol Med Rep. Feb 2015. http://www.ncbi.nlm.nih.gov/pubmed/25351792
  101. Tang AQ, Cao XC, Tian L et al. Apigenin inhibits the self-renewal capacity of human ovarian cancer SKOV3‑derived sphere-forming cells. Mol Med Rep. Mar 2015. http://www.ncbi.nlm.nih.gov/pubmed/25405327
  102. Seo HS, Ku JM, Choi HS et al. Induction of caspase-dependent apoptosis by apigenin by inhibiting STAT3 signaling in HER2-overexpressing MDA-MB-453 breast cancer cells. Anticancer Res. Jun 2014. http://www.ncbi.nlm.nih.gov/pubmed/24922650
  103. Wu DG, Yu P, Li JW et al. Apigenin potentiates the growth inhibitory effects by IKK-β-mediated NF-κB activation in pancreatic cancer cells. Toxicol Lett. Jan 3, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24148603
  104. Owen RW et al. Olives and olive oil in cancer prevention. Eur J Cancer Prev. Aug 2004. http://www.ncbi.nlm.nih.gov/pubmed/15554560
  105. Cárdeno A et al. An up-date of olive oil phenols in inflammation and cancer: molecular mechanisms and clinical implications. Curr Med Chem. 2013. http://www.ncbi.nlm.nih.gov/pubmed/23834184
  106. Calabriso N et al. Extra virgin olive oil rich in polyphenols modulates VEGF-induced angiogenic responses by preventing NADPH oxidase activity and expression. J Nutr Biochem. Feb 2016 . http://www.ncbi.nlm.nih.gov/pubmed/26878779
  107. Lamy S et al. Olive oil compounds inhibit vascular endothelial growth factor receptor-2 phosphorylation. Exp Cell Res. Mar 10, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24326154
  108. Scoditti E et al. Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch Biochem Biophys. Nov 15, 2012 . http://www.ncbi.nlm.nih.gov/pubmed/22595400
  109. Psaltopoulou T et al. Olive oil intake is inversely related to cancer prevalence: a systematic review and a meta-analysis of 13,800 patients and 23,340 controls in 19 observational studies. Lipids Health Dis. Jul 2011. http://www.ncbi.nlm.nih.gov/pubmed/21801436
  110. Stoneham M et al. Olive oil, diet and colorectal cancer: an ecological study and a hypothesis. JEpidemiol Community Health. Oct. 2000. http://www.ncbi.nlm.nih.gov/pubmed/10990479
  111. Buckland G, Gonzalez CA. The role of olive oil in disease prevention: a focus on the recent epidemiological evidence from cohort studies and dietary intervention trials. Br J Nutr. Apr. 2015. http://www.ncbi.nlm.nih.gov/pubmed/26148926
  112. Khuda-Bukhsh et al. Molecular Approaches Toward Targeted Cancer Prevention with Some Food Plants and Their Products: Inflammatory and Other Signal Pathways. NUNR CANCER. Feb 2014. http://www.ncbi.nlm.nih.gov/pubmed/24377653
  113. Sakina M. Petiwala and Jeremy J. Johnson. Diterpenes from rosemary ( Rosmarinus officinalis ): Defining their potential for anti-cancer activity. Elsevier . 2015. https://www-clinicalkey-com/#!/content/playContent/1-s2.0-S0304383515004462?returnurl=null&referrer=null
  114. Al-Menhali A et al. Thymus vulgaris (thyme) inhibits proliferation, adhesion, migration, and invasion of human colorectal cancer cells. J Med Food. Jan 2015. http://www.ncbi.nlm.nih.gov/pubmed/25379783
  115. Arami S, Ahmadi A, Haeri SA. The radioprotective effects of Origanum vulgare extract against genotoxicity induced by (131)I in human blood lymphocyte. Cancer Biother Radiopharm. Apr 2013. http://www.ncbi.nlm.nih.gov/pubmed/23413802
  116. Weidner C et al. Melissa officinalis extract induces apoptosis and inhibits proliferation in colon cancer cells through formation of reactive oxygen species. Phytomedicine. Feb 15, 2015 . http://www.ncbi.nlm.nih.gov/pubmed/25765831
  117. Jahanban-Esfahlan A et al. Anti Proliferative Properties of Melissa officinalis in Different Human Cancer Cells. Asian Pac J Cancer Prev. 2015. http://www.apocpcontrol.org/paper_file/issue_abs/Volume16_No14/5703-5707%202.5%20Akram%20Jahanban-Esfahlan-Revised.pdf
  118. Queiroz RM et al. Apoptosis-inducing effects of Melissa officinalis L. essential oil in glioblastoma multiforme cells. Cancer Invest. Jul 2014 . http://www.ncbi.nlm.nih.gov/pubmed/24745610
  119. Maryam Keshavarz et al. In vitro and ex vivo antiangiogenic activity of Salvia officinalis. Phytotherapy Research. JUN 1, 2010. http://onlinelibrary.wiley.com/doi/10.1002/ptr.3168/abstract
  120. Han Y et al. Separation, characterization and anticancer activities of a sulfated polysaccharide from Undaria pinnatifida. Int J Biol Macromol. Feb 2016. http://www.ncbi.nlm.nih.gov/pubmed/26616455
  121. Kim KJ, Yoon KY, Lee BY. Low molecular weight fucoidan from the sporophyll of Undaria pinnatifida suppresses inflammation by promoting the inhibition of mitogen-activated protein kinases and oxidative stress in RAW264.7 cells. Fitoterapia. Dec 2012 . http://www.ncbi.nlm.nih.gov/pubmed/23006539
  122. Hongming Teng et al. Fucoidan Suppresses Hypoxia-Induced Lymphangiogenesis and Lymphatic Metastasis in Mouse Hepatocarcinoma. Mar Drugs. Jun 2015. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483642/
  123. Peisheng Wang et al. Anti-Metastasis Effect of Fucoidan from Undaria pinnatifida Sporophylls in Mouse Hepatocarcinoma Hca-F Cells. PLoS One.  Aug 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4146566/
  124. Hye-Jin Boo et al. The Anticancer Effect of Fucoidan in PC-3 Prostate Cancer Cells. Mar Drugs. Aug 2013. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766877/
  125. Ghislain Moussavou et al. Anticancer Effects of Different Seaweeds on Human Colon and Breast Cancers. Mar. Drugs. Sep 2014. http://www.mdpi.com/1660-3397/12/9/4898/htm
  126. Boo HJ et al. Fucoidan from Undaria pinnatifida induces apoptosis in A549 human lung carcinoma cells. Phytother Res. Jul 2011 . http://www.ncbi.nlm.nih.gov/pubmed/21452391
  127. Sheng Kelvin Wang et al. Extracts from New Zealand Undaria pinnatifida Containing Fucoxanthin as Potential Functional Biomaterials against Cancer in Vitro. J Funct Biomater. Jun 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099972/
  128. Yu RX et al. Effects of fucoxanthin on proliferation and apoptosis in human gastric adenocarcinoma MGC-803 cells via JAK/STAT signal pathway. Eur J Pharmacol. Apr 2011. http://www.ncbi.nlm.nih.gov/pubmed/21187083
  129. Kim KN et al. Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway. Toxicol In Vitro. Sep 2010. http://www.ncbi.nlm.nih.gov/pubmed/20594983
  130. Guan H et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. May 2009. http://www.ncbi.nlm.nih.gov/pubmed/19190105
  131. Braganza MZ et al. Adolescent and mid-life diet and subsequent risk of thyroid cancer in the NIH-AARP diet and health study. Int J Cancer.  Nov 15, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25974060
  132. Michikawa T et al. Seaweed consumption and the risk of thyroid cancer in women: the Japan Public Health Center-based Prospective Study. Eur J Cancer Prev. May 2012. http://www.ncbi.nlm.nih.gov/pubmed/22414981
  133. Wang C et al. Prospective study of seaweed consumption and thyroid cancer incidence in women: the Japan collaborative cohort study. Eur J Cancer Prev. May 2016. http://www.ncbi.nlm.nih.gov/pubmed/26011104
  134. Tai Sheng Yeh, Nu Hui Hung, Tzu Chun Lin. Analysis of iodine content in seaweed by GC-ECD and estimation of iodine intake. journal of food and drug analysis. Jun 2014. http://www.sciencedirect.com/science/article/pii/S1021949814000155
  135. Koníčková R et al. Anti-cancer effects of blue-green alga Spirulina platensis, a natural source of bilirubin-like tetrapyrrolic compounds. Ann Hepatol. Mar-Apr 2014 . http://www.annalsofhepatology.com/revista/numeros/2014/15_142_v13n2_2014_AnticancerEffects.pdf
  136. Pham TX, Lee JY. Anti-Inflammatory Effect of Spirulina platensis in Macrophages Is Beneficial for Adipocyte Differentiation and Maturation by Inhibiting Nuclear Factor-κB Pathway in 3T3-L1 Adipocytes. J Med Food. Jun 2016 . http://www.ncbi.nlm.nih.gov/pubmed/27206252
  137. Maja Kozarski et al. Antioxidants of Edible Mushrooms. Molecules . Oct 2015. http://www.mdpi.com/1420-3049/20/10/19489/htm 
  138. Xu T, Beelman RB, Lambert JD. The cancer preventive effects of edible mushrooms. Anticancer Agents Med Chem. Dec 2012. http://www.ncbi.nlm.nih.gov/pubmed/22583406 
  139. Martin KR, Brophy SK. Commonly consumed and specialty dietary mushrooms reduce cellular proliferation in MCF-7 human breast cancer cells. Exp Biol Med (Maywood). Nov 2010. http://www.ncbi.nlm.nih.gov/pubmed/20921274 
  140. Lee JS et al. Grifola frondosa (Maitake mushroom) water extract inhibits vascular endothelial growth factor-induced angiogenesis through inhibition of reactive oxygen species and extracellular signal-regulated kinase phosphorylation. J Med Food. Dec 2008 . http://www.ncbi.nlm.nih.gov/pubmed/19053855 
  141. Fritz H et al. Polysaccharide K and Coriolus versicolor extracts for lung cancer: a systematic review. Integr Cancer Ther. May 2015. http://www.ncbi.nlm.nih.gov/pubmed/25784670 
  142. Piotrowski J et al. Immunomodulatory and antitumor properties of polysaccharide peptide (PSP). Postepy Hig Med Dosw (Online). Jan 2015. http://www.ncbi.nlm.nih.gov/pubmed/25614677 
  143. Shinil K. Shah et al. An Evidence-Based Review of a Lentinula edodes Mushroom Extract as Complementary Therapy in the Surgical Oncology Patient. JPEN J Parenter Enteral Nutr. Jul 2011. http://pen.sagepub.com/content/35/4/449.long 
  144. Kenji Ina et al. The Use of Lentinan for Treating Gastric Cancer. Anticancer Agents Med Chem. Jun 2013. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664515/ 
  145. Kim Y, Seo JH, Kim H. β-carotene and lutein inhibit hydrogen peroxide-induced activation of NF-κB and IL-8 expression in gastric epithelial AGS cells. J. Nutr. Sci. Vitaminol. 2011. http://www.ncbi.nlm.nih.gov/pubmed/21908944 
  146. Natália F. Haddad et al. Lycopene and Beta-Carotene Induce Growth Inhibition and Proapoptotic Effects on ACTH-Secreting Pituitary Adenoma Cells. PLoS One. May 2013. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647049/ 
  147. Yoona Park et al. β-Carotene-induced apoptosis is mediated with loss of Ku proteins in gastric cancer AGS cells. Genes Nutr. Jul 2015. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434228/ 
  148. Jeurnink SM et al. Plasma carotenoids, vitamin C, retinol and tocopherols levels and pancreatic cancer risk within the European Prospective Investigation into Cancer and Nutrition: a nested case-control study: plasma micronutrients and pancreatic cancer risk. Mar 15, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25175624 
  149. A. Heather Eliassen et al. Circulating Carotenoids and Risk of Breast Cancer: Pooled Analysis of Eight Prospective Studies. J Natl Cancer Inst. Dec 19, 2012. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525817/ 
  150. Nicholas J. Ollberding et al. Prediagnostic circulating carotenoid levels and the risk of non-Hodgkin lymphoma: the Multiethnic Cohort. Blood. May 1, 2012. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382940/
  151. Hakim IA, Harris RB, Ritenbaugh C. Citrus peel use is associated with reduced risk of squamous cell carcinoma of the skin. Nutr Cancer. 2000. http://www.ncbi.nlm.nih.gov/pubmed/11142088
  152. Jessica A. Miller et al. Human breast tissue disposition and bioactivity of limonene in women with early stage breast cancer. Cancer Prev Res (Phila).  Jun 2013.
  153. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692564/
  154. Jung-Kook Song, Jong-Myon Bae. Citrus Fruit Intake and Breast Cancer Risk: A Quantitative Systematic Review. J Breast Cancer. Mar 2013. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625773/
  155. Im SJ, Kim JH, Kim MY. Evaluation of bioactive components and antioxidant and anticancer properties of citrus wastes generated during bioethanol production. Nat Prod Commun. Apr 2014.http://www.ncbi.nlm.nih.gov/pubmed/24868862
  156. Liwen Wang et al. Anticancer Activities of Citrus Peel Polymethoxyflavones Related to Angiogenesis and Others. Biomed Res Int. Aug 28, 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163462/
  157. Hao M et al. Comparative studies on the anti-tumor activities of high temperature- and pH-modified citrus pectins. Food Funct. Jun 2013. http://www.ncbi.nlm.nih.gov/pubmed/23673419
  158. Anqiang Wang et al. Citrus Fruit Intake Substantially Reduces the Risk of Esophageal Cancer: A Meta-Analysis of Epidemiologic Studies. Medicine (Baltimore). Sep 2015. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616874/
  159. Bae JM, Lee EJ, Guyatt G. Citrus fruit intake and pancreatic cancer risk: a quantitative systematic review. Pancreas. Mar 2009. http://www.ncbi.nlm.nih.gov/pubmed/18824947
  160. Song JK1, Bae JM. Citrus fruit intake and breast cancer risk: a quantitative systematic review. J Breast Cancer.  Mar 2013. http://www.ncbi.nlm.nih.gov/pubmed/23593085
  161. Bae JM, Lee EJ, Guyatt G. Citrus fruit intake and stomach cancer risk: a quantitative systematic review. Gastric Cancer. 2008. http://www.ncbi.nlm.nih.gov/pubmed/18373174
  162. Wu S et al. Citrus consumption and risk of basal cell carcinoma and squamous cell carcinoma of the skin. Carcinogenesis. Oct 2015. http://www.ncbi.nlm.nih.gov/pubmed/26224304
  163. Joydeb Kumar Kundu, Kyung-Soo Chun. The Promise of Dried Fruits in Cancer Chemoprevention. Asian Pac J Cancer Prev. 2014. http://www.ncbi.nlm.nih.gov/pubmed/24870720
  164. Vizzotto M et al. Polyphenols of selected peach and plum genotypes reduce cell viability and inhibit proliferation of breast cancer cells while not affecting normal cells. Food Chem. Dec 1, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24996346
  165. Noratto G et al. Identifying peach and plum polyphenols with chemopreventive potential against estrogen-independent breast cancer cells. J Agric Food Chem. Jun 24, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19530711
  166. Polyphenolics from peach (Prunus persica var. Rich Lady) inhibit tumor growth and metastasis of MDA-MB-435 breast cancer cells in vivo. J Nutr Biochem. Jul 2014. http://www.ncbi.nlm.nih.gov/pubmed/24745759
  167. Lu QY et al. Inhibition of prostate cancer cell growth by an avocado extract: role of lipid-soluble bioactive substances. J Nutr Biochem. Jan 2015. http://www.ncbi.nlm.nih.gov/pubmed/15629237
  168. Labrecque L et al. Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis. Apr 2005. http://www.ncbi.nlm.nih.gov/pubmed/15661805
  169. Gary D. Stoner et al. . Cancer Prevention with Freeze-dried Berries and Berry Components. Semin Cancer Biol. Oct 1, 2008. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2196225/
  170. Knobloch TJ et al. Suppression of Proinflammatory and Prosurvival Biomarkers in Oral Cancer Patients Consuming a Black Raspberry Phytochemical-Rich Troche. Cancer Prev Res (Phila). Feb 2016. http://www.ncbi.nlm.nih.gov/pubmed/26701664
  171. Hanausek M et al. Detoxifying cancer causing agents to prevent cancer. Integr Cancer Ther. Jun 2003. http://www.ncbi.nlm.nih.gov/pubmed/15035900
  172. Adhami VM et al. Cancer chemoprevention by pomegranate: laboratory and clinical evidence. Nutr Cancer. 2009. http://www.ncbi.nlm.nih.gov/pubmed/20155621
  173. Pantuck AJ et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. Jul 1, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16818701
  174. Jaganathan SK et al. . Role of pomegranate and citrus fruit juices in colon cancer prevention. World J Gastroenterol. Apr 28, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24782614
  175. Pantuck AJ et al. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. Prostate Cancer Prostatic Dis. Sep2015.  http://www.nature.com/pcan/journal/v18/n3/full/pcan201532a.html
  176. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol. Jun 2000. http://www.ncbi.nlm.nih.gov/pubmed/10843709
  177. Azar Hosseini, Ahmad Ghorbani. Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J Phytomed. Mar-Apr 2015. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418057/
  178. O’Byrne DJ et al. Comparison of the antioxidant effects of Concord grape juice flavonoids α-tocopherol on markers of oxidative stress in healthy adults. Am J Clin Nutr. Dec 2002 . http://ajcn.nutrition.org/content/76/6/1367.long
  179. Lee SH et al. Anti-angiogenic effects of resveratrol in combination with 5-fluorouracil on B16 murine melanoma cells. Mol Med Rep. Aug 2015 . https://www.spandidos-publications.com/mmr/12/2/2777
  180. Nitta J et al. Weight Gain and Alcohol Drinking Associations with Breast Cancer Risk in Japanese Postmenopausal Women - Results from the Japan Collaborative Cohort (JACC) Study. Asian Pac J Cancer Prev. 2016. http://www.ncbi.nlm.nih.gov/pubmed/27039786
  181. Sohee Park et al. Attributable fraction of alcohol consumption on cancer using population-based nationwide cancer incidence and mortality data in the Republic of Korea. BMC Cancer. Jun 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065076/
  182. Wu S et al. Alcohol consumption and risk of cutaneous basal cell carcinoma in women and men: 3 prospective cohort studies. Am J Clin Nutr. Nov 2015. http://www.ncbi.nlm.nih.gov/pubmed/26423390
  183. Fang X et al. Landscape of dietary factors associated with risk of gastric cancer: A systematic review and dose-response meta-analysis of prospective cohort studies. Eur J Cancer. Dec 2015. http://www.ncbi.nlm.nih.gov/pubmed/26589974
  184. Wu L et al. Nut consumption and risk of cancer and type 2 diabetes: a systematic review and meta-analysis. Nutr Rev. Jul 2015. http://www.ncbi.nlm.nih.gov/pubmed/26081452
  185. Narinder Kaur, Vishal Chugh, Anil K. Gupta. Essential fatty acids as functional components of foods- a review. J Food Sci Technol. Oct 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190204/#CR101
  186. Falasca M, Casari I, Maffucci T. Cancer Chemoprevention With Nuts. JNCI J Natl Cancer Inst. Apr 2014. http://jnci.oxfordjournals.org/content/106/9/dju238.long
  187. Jenab M et al. Association of nut and seed intake with colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev.  2004. http://cebp.aacrjournals.org/content/13/10/1595.abstract?ijkey=9ef492b53015c6352daaf056256181dbc40aff2e&keytype2=tf_ipsecsha
  188. Bao Y et al. Nut consumption and risk of pancreatic cancer in women. Br J Cancer. 2013. http://www.nature.com/bjc/journal/v109/n11/full/bjc2013665a.html
  189. Elkady AI, Hussein RA, El-Assouli SM. Mechanism of Action of Nigella sativa on Human Colon Cancer Cells: the Suppression of AP-1 and NF-κB Transcription Factors and the Induction of Cytoprotective Genes. Asian Pac J Cancer Prev. 2015. http://www.ncbi.nlm.nih.gov/pubmed/26625825
  190. Hagag AA et al. Therapeutic value of black seed oil in methotrexate hepatotoxicity in Egyptian children with acute lymphoblastic leukemia. Infect Disord Drug Targets. 2015. http://www.ncbi.nlm.nih.gov/pubmed/25809628
  191. Lidia López-Barrios et al. Bioactive Peptides and Hydrolysates from Pulses and Their Potential Use as Functional Ingredients. Journal of food science . Feb 18, 2014. http://onlinelibrary.wiley.com/doi/10.1111/1750-3841.12365/abstract
  192. Yau Sang Chan et al. A Glucosamine-Specific Lectin from Green Dragon No. 8 Beans (Phaseolus vulgaris) Induced Apoptosis on Nasopharyngeal Carcinoma Cells. Evid Based Complement Alternat Med. Jul 2015. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531188/
  193. Dongyan Tang et al. A review of phytochemistry, metabolite changes, and medicinal uses of the common food mung bean and its sprouts (Vigna radiata). Chem Cent J. Jan 17, 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899625/
  194. Karina Huber et al. Effect of Thermal Processing and Maceration on the Antioxidant Activity of White Beans. PLoS One. Jul 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081045/
  195. Jain MG et al. Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. Nutr Cancer. 1999. http://web.a.ebscohost.com/ehost/detail/detail?sid=B7508fc0-14ca-4159-9e77-39d6ead0801c%40sessionmgr4002&vid=0&hid=4107&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d&preview=false#db=mnh&AN=10578485
  196. Young RP, Hopkins RJ. A review of the Hispanic paradox: time to spill the beans? Eur Respir Rev. Dec 2014. http://err.ersjournals.com/content/23/134/439.long
  197. Mueller SO et al. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci. Jul 2004. http://www.ncbi.nlm.nih.gov/pubmed/15084758
  198. Anne M. Weaver et al. Abstract A79: Usual intakes of total and specific isoflavones in association with breast tumor characteristics. Cancer Prevention Research. Nov 2010. http://cancerpreventionresearch.aacrjournals.org/content/3/12_Supplement/A79.abstract
  199. Shu XO et al. Soy food intake and breast cancer survival. JAMA. Dec 9, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19996398
  200. Chang HC et al. Soypeptide lunasin in cytokine immunotherapy for lymphoma. Cancer Immunol Immunother. Mar 2014. http://www.ncbi.nlm